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MAP/Microtubule Affinity Regulating Kinase 4 (MARK4) belongs to a highly conserved family of 
serine–threonine kinases (MARKs) that are able to phosphorylate the microtubule associated 
proteins (MAPs), and cause these proteins to detach from microtubules (MTs) increasing 
microtubules dynamics. MARKs kinases represent the mammalian homologues of PAR-1, a protein 
involved in establishment of the cell shape and polarity in lower eukaryotes. 
The MARK4 gene is located at 19q13.2 and encodes at least two alternatively spliced isoforms, 
MARK4L and MARK4S, which have an identical protein structure apart from the C-terminal 
region. The two isoforms are differentially expressed in human tissues, particularly in the central 
nervous system (CNS). Several studies reported that MARK4S is expressed in normal brain tissue 
and neurons, suggesting that this isoform has a role in neuronal differentiation. Conversely, 
MARK4L is up-regulated in glioma and neural progenitor cells, pointing to a possible role of this 
isoform in cell proliferation. Recently, we highlighted an increasingly subverted 
MARK4L/MARK4S ratio, with prevalence of MARK4L, in glioblastoma and glioblastoma-derived 
cancer stem cells, that recapitulate the expression profiling of neural stem cells. These findings 
suggest that the expression of the two MARK4 isoforms is tightly regulated during the 
proliferation/differentiation of neural stem cells and changes in their expression levels may be a 
molecular marker of tumour transformation.  
Unlike the other members of the family (MARK1, MARK2 and MARK3), that exhibit uniform 
cytoplasmic localisation, both MARK4 isoforms localise at the centrosomes and in the midbody, 
supporting their involvement in mitotic division and cytokinesis. 
To elucidate the role played by MARK4 isoforms in cell cycle progression and in the regulation of 
the cytoskeleton, we monitored the activation status of MARK4 during the cell cycle and performed 
overexpression experiments in fibroblasts and glioma cell lines. 
We showed that despite MARK4 is expressed across all the cell cycle phases, its active form, 
phosphorylated at the Thr214 residue, is prevalent in mitosis. Phospho-MARK4 is detected in 
centrosomes at all mitotic stages and in the midbody during cytokinesis. Conversely, only a fraction 
of interphase centrosomes show phospho-MARK4 positive signals.  
Overexpression experiments on fibroblasts and glioma cell lines demonstrated the role of MARK4 
in the regulation of cytoskeleton dynamics. Indeed overexpression of MARK4L or MARK4S led to 
a sharp decrease in microtubule density in both the cell systems, as monitored by 
immunofluorescence experiments. By contrast, overexpression of catalytically inactive 
MARK4L/MARK4S mutants, did not affect the microtubule network, indicating that the effects on 
MTs are dependent on the kinase activity of MARK4 and likely linked to MAPs phosphorylation. 
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Besides the effect on MT array, overexpressed MARK4L in fibroblasts showed a filamentous 
staining pattern, co-localising with vimentin, the core component of cytoskeleton intermediate 
filaments. In contrast, overexpressed MARK4S co-localised with vimentin to a lesser extent and 
only in few cells. 
The MARK4L-vimentin co-localisation was particularly evident in the perinuclear zone and in 
some overexpressing cells, the filaments appeared reshaped as compared to those in GFP-
transfected cells, and showed the formation of bundle structures. These alterations seem to be due to 
the kinase activity of MARK4L since overexpression of kinase dead mutants did not remodel the 
intermediate filaments.  
The overall data highlight MARK4 as a key component in the regulation of microtubules dynamics, 
and indicate vimentin as a plausible target of MARK4L activity, suggesting a wide-ranging 
influence of MARK4 on cytoskeleton. Moreover the dynamic involvement of active MARK4 in 
structure like centrosomes and midbody, crucial for mitosis and cytokinesis, point to a fundamental 
role for this kinase in the cell cycle.  
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1.MARK4: a member of the AMPK kinase family  
AMP-activated protein kinase (AMPK) is a conserved serine-threonine kinase involved in the 
regulation of cellular and whole-body energy homeostasis (Bright et al., 2009). AMPK is activated 
by different physiological and pathological stimuli that decrease cellular energy levels, increasing 
the AMP/ATP ratio (Hardie 2003).  
The activation of AMPK needs phosphorylation of threonine residue 172, located in the activation 
loop of the catalytic domain. Three upstream AMPK kinases have been identified: the Liver Kinase 
B1 (LKB1), a tumour suppressor protein kinase associated with Peutz-Jeghers Syndrome, the 
Ca
2+
/calmoduline-dependent protein kinase β and the transforming growth factor-β-activated kinase 
1 (TAK1). In addition to phosphorylation, AMPK is activated allosterically by AMP.  
Besides its effects on energy homeostasis, AMPK plays many different functions including 
regulation of mitochondrial biogenesis, cell polarity and cell growth and proliferation. 
Twelve kinases (BRSK1, BRSK2, NUAK1, NUAK2, SIK1, SIK2, SIK3, MARK1, MARK2, 
MARK3, MARK4 AND MELK), show high sequence homology with the AMPK kinase domain, 
and have been identified and grouped in the AMPK-related kinase family (Bright et al., 2009). 
These protein kinases have a similar structural organisation, and with the exception of MELK, can 
be activated by LKB1 upon phosphorylation of a conserved threonine. 
AMPK-related kinases are expressed in different tissues and are involved in the regulation of 
diverse processes including metabolism, cell polarity, cell cycle, insulin signalling (Figure 1). 
 
Figure 1. Tissue expression and functions of AMPK-related kinases (Modified from Bright et al., 2009).  
 
Among the AMPK-related kinases, substantial evidences have been acquired on the important roles 
played by MARK proteins in crucial processes like cell polarity and cell division. 
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2.The MARK protein family 
The MARK proteins (Microtubule associated protein/Microtubule affinity regulating kinases) 
belong to a family of serine/threonine kinases that were originally identified by their ability to 
phosphorylate microtubule associated proteins (MAPs) (including tau, MAP2, MAP4 and 
doublecortin) at a specific site (serine in the KXGS motifs) in the microtubule binding repeats. As 
consequence of phosphorylation, MAPs decrease their affinity for microtubules (MTs), detach from 
them and increase their dynamics (leading to MT network destabilisation) (Drewes et al., 1997). 
In mammals the MARK family consists of four members (MARK1, MARK2, MARK3 and 
MARK4) and additional isoforms arise by alternative splicing. 
 
2.1 Protein Structure 
All the four MARK proteins have a conserved domain organisation, similar to the other AMPK-
related kinases, and can be divided into six sequence segments, shown in Figure 2 (Timm et al., 
2008; Marx et al., 2010).  
 
 
Figure 2. Schematic representation of MARK protein structure. 
 
From the N to the C terminus they are: 
 
 The N-terminal header (N), which function is still unknown. This domain is usually 
different for each MARK protein and is missing or considerably reduced in size in some 
isoforms. 
 The catalytic domain, the region with the highest homology among the four MARK 
proteins (~90%), presents a bi-lobal structure typical of protein kinases, with an active site 
cleft between the two lobes. The smaller N-terminal lobe consists of five β-strands and a 
single α-helix, while the larger C-terminal lobe is mostly folded into an α-helical structure. 
Both lobes contribute structural elements to the active site, consisting of: the P-loop 
(phosphate-binding), the catalytic loop and the activation loop (also called T-loop). The P-
loop helps to position the ATP γ-phosphate to be transferred to the substrate’s 
phosphorylation sites. The catalytic domain presents an RD motif, consisting of a 
catalytically active aspartate, preceded by an arginine residue. The T-loop contains a 
conserved sequence (LDTFCGSPP) where the threonine and serine residues are the 
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phosphorylation target. When MARK proteins are inactive, the T-loop is disordered, and 
folds over the cleft, blocking the access of ATP and substrate proteins. Phosphorylation of 
the conserved threonine in the T-loop, activates the protein, triggering its reorientation and 
stabilisation. The activation loop folds out of the catalytic cleft, that becomes thus accessible 
to the substrate(s) and ATP. 
 The linker is a short stretch of amino acids, that starts with a charged four residues motif 
that resembles the common docking (CD) site in MAP kinases. This region may bind 
interactors or co-factors. 
 The ubiquitin associate domain (UBA) is a small and globular region, consisting of three α-
helices folded in a characteristic helical bundle. The domain is present in all the AMPK-
related kinases, and has sequence homology with ubiquitin-associated proteins, but at 
difference of them, it is differently and unusually folded and probably does not bind 
ubiquitin. It has been suggested that the UBA domain of AMPK-related kinases has evolved 
from canonical UBA domains and has then lost the capacity of ubiquitin binding in favour 
of the ability to interact with the kinase domain (Murphy et al., 2007). Indeed it has been 
demonstrated that UBA binds the N-lobe of MARK catalytic domain, locking it in an open 
inactive conformation (Panneerselvam et al., 2006). Based on these features the interaction 
of UBA could have two different consequences on MARK activity. First, UBA can exert an 
autoinhibitory role maintaining the open conformation that prevents ATP and substrates 
binding (Panneerselvam et al., 2006). On the other hand this conformation could increase 
the accessibility of the activation loop for activating or deactivating kinases (Murphy et al., 
2007). Accordingly it has been found that UBA is necessary for LKB1- mediated activation, 
despite not being the docking site for this upstream kinase (Jaleel et al., 2006). In addition 
an intact UBA appears to be required for reaching full activity even if MARK protein is 
already phosphorylated at the threonine in the T-loop (Jaleel et al., 2006). 
 The spacer is the most variable region among the MARK kinases, varying in size between 
290 and 330 residues. This domain maintains a native unfolded status and is important for 
the regulation of MARK activity, as it contains sites that are target of different kinases. 
 The C-terminal tail domain is constituted by 100 amino acid residues and comprises the 
Kinase associated domain 1 (KA1), that is conserved among the AMPK-related kinase 
family. This region has a hydrophobic, concave surface surrounded by positively charged 
amino acids. It has been suggested that this highly conserved surface may interact with 
negatively charged sequences present in the MARK catalytic domain or CD region, 
regulating the MARK activity (Tochio et al., 2006). The C-terminal tail domain could be 
11 
 
another autoinhibitory domain, in addition to UBA. It has been also proposed that the KA1 
domain is involved in protein localisation (Tochio et al., 2006). 
 
2.2 Regulation of MARK proteins 
MARK proteins, as above outlined, present different domains, that are important for the regulation 
of kinase activity through multiple pathways. In particular MARK activity, is finely tuned by 
various post-translational modifications including phosphorylation and ubiquitination and by 
interaction with other proteins (Figure 3). 
 
Figure 3. Schematic representation of regulatory pathways of MARKs. 
 
2.2.1 MARKs regulation by phosphorylation  
The activity of MARK proteins can be enhanced or reduced by the phosphorylation of specific 
threonine or serine residues, present in either the kinase domain and the spacer region (Matenia & 
Mandelwkow 2009).  
The activation of MARK protein requires the phosphorylation of a conserved threonine present in 
the T-loop (T215 in MARK1, T208 in MARK2, T211 in MARK3 and T214 in MARK4) by two 
different upstream activating kinases: LKB1 (Lizcano et al., 2004) and MARK kinase 
(MARKK/TAO1) (Timm et al., 2003).  
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LKB1 is a tumour suppressor gene, which loss-of-function mutations are the molecular cause of 
Peutz–Jeghers syndrome (OMIM#175200), an autosomal dominant disorder characterised by the 
predisposition to a wide spectrum of benign and malign tumours, in particular gastrointestinal 
polyps and colon and breast cancers (Alessi et al., 2006). Many different studies have demonstrated 
that LKB1 is able to interact, phosphorylate and activate various kinases including AMPK and all 
AMPK-related kinases apart from MELK. In mammalian cells LKB1 activity and localisation is 
regulated through its interaction with two proteins: the pseudokinase STE20-related adaptor 
(STRAD), and mouse protein 25 (MO25) (Baas et al., 2003; Boudeau et al., 2003; Brajenovic et al., 
2004). 
MARKK is a kinase, that belongs to the STE20 kinase family and shows high homology with the 
TAO-1 (thousand-and-one amino acid) protein (Timm et al., 2003). 
It has been demonstrated that the activated Calcium/calmodulin-dependent protein kinase I 
(CaMKI) interacts with the kinase domain of MARK2, phosphorylating it at a novel site (Uboha et 
al., 2007).  
The activity of MARKs can be also negatively regulated by different kinases phosphorylating 
specific residues.  
The glycogen synthase kinase 3β (GSK3β) phosphorylates a conserved serine present in the T-loop 
three amino acids after the threonine activation site (S219 in MARK1, S212 in MARK2, S215 in 
MARK3 and S218 in MARK4) (Timm et al., 2008). The phosphorylation of this residue causes the 
inhibition of MARK activity, even when the conserved threonine is phosphorylated by LKB1 or 
MARKK. It has been shown that this particular serine is fundamental for the stabilisation of the 
activation loop. In the inactive state, the T-loop is folded into the catalytic cleft, obstructing the 
entry of both ATP and substrate. Following the phosphorylation of the conserved threonine, the 
activation loop folds out, opening the cleft for the substrate; in this configuration, the serine 
establishes hydrogen bonds with the catalytic aspartate. These bonds together with the interaction of 
the phospho-threonine, block the T-loop in the open conformation, which is crucial for the kinase 
activity. The phosphorylation of the conserved serine disrupts the interaction that stabilises the 
molecules, and the same result is achieved when this residue is mutated to alanine (Timm et al., 
2008). 
The MARK proteins also interact with the atypical Protein Kinase C (aPKC), a kinase involved in 
the regulation of cell polarity. aPKC phosphorylate MARK2 at T595 in the spacer region, 
enhancing the interaction with 14-3-3/Par-5 protein. This modification down regulates MARK 
activity and stimulates its dissociation from the lateral membrane in polarised cells (Suzuki et al., 
2004; Hurov et al., 2004). aPKC is also able to phosphorylate MARK3 at an analogous site, 
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suggesting that the MARK isoforms might have redundant functions in the cells (Hurov et al. 
2004). It has been demonstrated that MARK4 interacts with PKC-λ, another kinase involved in cell 
polarity (Brajenovic et al., 2004). 
The human PIM 1 kinase, a member of CaMK superfamily, inhibits MARK3 activity by 
phosphorylating a serine residue in the catalytic domain (Bachmann et al., 2004). 
 
 
2.2.2 Ubiquitination  
Based on the presence of the UBA domain, it has been suggested that binding of ubiquitin can 
regulate MARKs activity. Recently it has been shown that MARK4 and NUAK2 (an AMPK-related 
kinase) can be polyubiquitinated in vivo, and are deubiquitinated through the interaction with the 
deubiquitinating enzyme USP9X (Ubiquitin Specific Protease-9). Ubiquitin modifications were 
thought to be involved in the regulation of phosphorylation and activation by LKB1, because 
MARK4 and NUAK2 mutants which do not bind USP9X are hyperubiquitinated, unphosphorylated 
and thus inactive (for more details see chapter 3.3 Regulation of MARK4) (Al-Hakim et al., 2008).  
 
 
2.2.3 Regulation of MARK activity by protein interaction 
Besides phosphorylation and ubiquitination the interaction between MARKs and other proteins 
contributes to modulating its kinase activity. 
It has been demonstrated that the adaptor proteins 14-3-3 (Par-5) can interact with MARK through 
two different ways: 14-3-3 can bind the catalytic domain independently of the phosphorylation 
status (Benton et al., 2003) or alternatively this protein can interact with the spacer region following 
aPKC phosphorylation (Hurov et al., 2004). These interactions inhibit MARK activity, probably by 
stabilising the interaction between the tail domain with the amino terminal or the kinase domain. In 
addition the binding of 14-3-3 proteins regulates MARK spatially, altering its localisation. 
The kinase activity of MARK2 is also inhibited by the interaction with the ste20-kinase PAK5. The 
PAK (p21-activated kinases) proteins are serine/threonine kinases involved in the regulation of 
different processes including cell cycle progression and cytoskeleton dynamics. PAK5 is able to 
inhibit MARK2 activity by the interaction of their respective catalytic domains being MARK 
phosphorylation status irrelevant for this binding (Matenia et al., 2005). 
The CD domain, present in all MARK isoforms, could act as site for the binding of various 
effectors similarly to what observed in MAP kinases (Tanoue et al., 2003). 
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2.2.4 Other mechanisms of MARK regulation 
As previously introduced, the UBA and KA1 domains can be involved in the auto-regulation of 
MARK activity, by interacting with the catalytic domain. 
Dimerization is a novel possible mechanism for autoregulation of MARK activity, as observed for 
many different kinases (Marx et al., 2010). MARK proteins crystallise in vitro as dimers with the 
two molecules covalently linked by disulphite bridges between T-loops. In this conformation the 
proteins are inactive, due to the open conformation assumed by the catalytic domain. Despite 
dimerization could occur also in living cells evidence for in vivo MARK dimerization is still lacking 
(Marx et al., 2010). 
 
 
2.3 MARK orthologous genes in lower eukaryotes  
The mammalian MARK proteins show significant homology with numerous kinases present in 
lower eukaryotes, and in particular with that encoded by the C. elegans PAR-1 gene. PAR-1 is one 
of the six partitioning defective genes (PAR 1-6), which mutation disorganises the asymmetric cell 
division of the zygote (Drewes et al., 1998). The PAR proteins cooperate in the formation of a 
polarised cell axis, which is essential for establishing the embryonic body axis. In particular the 
PAR-1 proteins localise in the posterior cortex, that develops into the germ cell line, and its kinase 
activity is fundamental for the distribution of the P granules. These particles are initially distributed 
evenly throughout the cytoplasm, but, before the first zygote cleavage, they move into the posterior 
pole always ending up in the germline in the following asymmetric cell divisions (Guo & 
Kemphues 1996).  
With the only exception of PAR-2, PAR orthologous genes have been found in Drosophila (Table 
1), where they are involved in the oocyte specification and in establishing the anterior- posterior 
polarity of the embryo (Riechmann et al., 2001).  
PAR orthologous genes have been discovered in mammals, and in particular four orthologous genes 
of C.elegans PAR-1 have been identified (Table 1) (Inglis et al., 1993; Drewes et al., 1997; 
Espinosa et al., 1998; Peng et al., 1998; Kato et al., 2001; Muller et al., 2001).  
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C. elegans D. melanogaster Mammals Domain/function mammals) 
PAR1 PAR1 MARK1/PAR1c 
MARK2/PAR1b 
MARK3/PAR1a 
MARK4/PAR1d 
Serine/Threonine kinases involved in 
microtubule dynamics 
PAR2 Not identified Not identified  
PAR3 PAR3/Bazooka PAR3/ASIP 
PAR3β 
PDZ domain 
PAR6, aPKC, JAM-1binding 
Necessary to form tight junctions 
PAR4 dLKB1 LKB1 Serine/Threonine kinase  
PAR-1 phosphorylation/activation  
PAR5 14-3-3 
14-3-3ξ 
14-3-3 ξ 14-3-3 domain 
PAR6 PAR6 PAR6a 
PAR6b 
PAR6c 
PAR6d 
PDZ and CRIB domainsPAR3 and aPKC 
binding 
Cdc42 Crumbs-PALS-PA7J binding 
Necessary to form tight junctions 
 
Table 1. PAR orthologous genes in Drosophila and mammalians (Modified from Baas et al., 2004). 
  
Orthologs of PAR-1/MARK protein have been identified back to fission yeast where they are called 
kin1. These proteins play a role in the regulation of cell polarity. In particular, in 
Schizosaccharomyces pombe kin1 is involved in establishing the rod-shaped morphology of yeast 
cells. Cells in which kin1 is deleted are still viable but are impaired in growth and round up. 
Interestingly these alterations can be in part rescued by the expression of human MARK, which re-
establishes bipolar growth (Drewes & Nurse 2003). 
The significant degree of sequence homology of proteins of the MARK-PAR-1-kin1family across 
evolutionarily distant organisms, suggests that these proteins operate in conserved signalling 
pathways controlling cell polarity. 
 
2.4 Localisation and function of MARK proteins 
It has been shown that MARK1, MARK2 and MARK3 present an uniform cytoplasm localisation, 
and are associated with the intracellular network. In addition MARK2 can be linked to the plasma 
membrane component (Drewes et al,. 1997; Trinczek et al., 2004).  
As described above the MARK proteins phosphorylate MAPs, regulating their affinity for MTs and 
thereby controlling microtubule dynamics. Based on this observation, MARK proteins can be 
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implicated in the control of many different cellular processes involving the microtubules network, 
such as cell polarity, centrosome formation, chromosome segregation and cytokinesis.  
Microtubule-dependent transport. It has been reported that MARK proteins can be involved in the 
regulation of microtubule-dependent transport. MAPs can compete with the motor proteins kinesin 
and dynein for the MT binding, thus inhibiting the transport of vesicle and organelles. MARK 
proteins, phosphorylating MAPs, cause their detachment from MTs and thereby facilitate the 
transport of particles (Mandelkow et al., 2004). Furthermore, it has been demonstrated that MARKs 
co-localise withe the clathrin-coated vesicles (CCV), highlighting a function of MARKs in 
regulating microtubule-dependent transport of CCV during endocytosis (Schmitt-Ulms et al. 2009). 
 
Cell polarity. MARK proteins are asymmetrically localised in mammalian epithelial cells (Bohm et 
al., 1997), and in particular MARK1 and MARK2 are necessary for polarisation of kidney or liver 
cells (Bohm et al., 1997; Cohen et al., 2004). MARK2 is involved in the polarisation of 
hippocampal neurones, by regulating the axon outgrowth. Indeed it has been found that MARK2 
silencing promotes the growth of multiple axons in neurons, whereas overexpression inhibits axon 
and dendritic formation (Chen et al., 2006; Terabayashi et al., 2007). MARK2 activity is inhibited 
by the PAR-3/PAR-6/aPKC complex, that promotes the axon establishment (Chen et al. 2006; 
Terabayashi et al. 2007). 
The role of MARK proteins in cell polarisation is also inferred by the observation that the 
Helicoibacter pylori CagA peptide interacts with MARK proteins, mimics their substrates and 
occupies the catalytic cleft inhibiting the kinase activity (Nesic et al., 2009). This leads to the 
alteration of cell polarity and the destruction of epithelial architecture.  
 
Neuron migration. The doublecortin (Dcx) is a microtubule associated protein, that can be 
phosphorylated by MARK proteins at the same KXGS motif shared by other MAPs. This protein is 
highly enriched in the leading processes of migrating neurons and the growth cone region of 
differentiating neurons. Dcx phosphorylation by MARK, regulating doublecortin affinity for 
microtubules, affects neuronal migration (Schaar et al., 2004). Indeed after MARK2 silencing, 
neurons of the developing neocortex fail to migrate beyond the intermediate zone, and do not 
acquire a bipolar morphology (Sapir et al., 2008).  
 
Cell Cycle control, cell signalling and subcellular localisation. Phosphorylation is a common 
mechanism to control the activity and to change the cellular localisation of proteins. 14-3-3 are 
phospho-binding proteins that can interact with different partners, regulating several essential 
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processes. MARK kinases, phosphorylating their target proteins, are involved in the regulation of 
several of them by creating a binding site for 14-3-3 proteins. 
MARK3 can phosphorylate the cell cycle regulatory phosphatase CdC25, mediating the binding 
between Cdc25 and 14-3-3 proteins, thus precluding Cdc25 activation of Cdc2/cyclin B complex by 
dephosphorylation, which is required for mitotic entry (Peng et al., 1998). Moreover MARK3 
phosphorylation and subsequently inhibition by Pim-1 promote cell cycle progression at the G2/M 
transition (Bachmann et al. 2004). 
Phosphorylation of the kinase suppressor of Raf-1 (KSR1) by MARK3 causes the binding of 14-3-3 
proteins, thus contributing to the regulation of the Ras-MAPK pathway (Muller et al., 2001). 
Class IIa histone deacetylases (HDACs) are present in both the cytoplasm and the nucleus, where 
they are involved in the repression of several developmental genes. MARK2 and 3 can 
phosphorylate HDACs, on their 14-3-3 binding site, and neutralise their repressive activity by 14-3-
3-mediated nuclear exclusion (Dequiedt et al., 2006). Similarly, MARK3 phosphorylates 
plakophilin 2 (PKP2), generating a 14-3-3 binding site, that drives PKP2 to the nucleus (Muller et 
al., 2003). 
 
Other physiological functions. Evidence based on experiments using MARK2 knockout mice 
prove that this kinase is involved in a variety of physiological functions like immune system 
homeostasis, learning and memory, fertility, growth and regulation of metabolism (Bessone et al., 
1999; Hurov et al. 2001; Hurov & Piwnica-Worms 2007; Segu et al., 2008). 
 
The MARK4 functions and cell localisation are reported in detail in the following paragraph. 
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3. MAP/Microtubule Affinity-Regulating Kinase 4 (MARK4) 
MARK4 is the less characterised member of the MARK kinase family. The MARK4 gene was 
discovered by Kato and colleagues in 2001, by analysing genes regulated by β-catenin/Tcf complex 
in a human hepatoma cell line (Kato et al., 2001). Based on its homology to MARK3, the gene was 
named MARKL1 (MARK1-like 1). 
  
3.1 MARK4 gene, alternative transcript and protein structure 
The MARK4 gene is located on chromosome 19q13.2, and consists of 18 exons. The MARK4 
transcripts can undergo alternative splicing, giving origin to two mature mRNA, that differ for the 
presence of exon 16 (Kato et al. 2001). They are: 
 the MARK4S (short) mRNA, the native isoform, that contains all the 18 exons, and is 3609 
bp long. This transcript encodes a 688 amino acid long protein, which molecular weight is 
around 75 kiloDalton (kDa). Due to the presence of exon 16 the stop-codon falls inside exon 
18, making the encoded protein to contain all the classical MARK domains, with the 
exception of the C-terminal KA1 domain (Figure 4). 
 
 
Figure 4. Schematic representation of MARK4S mRNA and protein. mRNA contains all exons but the stop 
codon is inside exon 18 leads to MARK4S isoform, that lacks the C-terminal KA1 domain. 
 
 MARK4L (long) mRNA, is 3529 bp long, and arises by the skipping of exon 16. The lack of 
exon 16 causes the shift of the reading frame, that changes the stop codon determining the 
synthesis of a longer protein (752 amino acids), which predicted molecular weight is 82,5 
kDa. The MARK4L protein presents all the typical MARK domains (Figure 5). 
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Figure 5. Schematic representation of MARK4L mRNA and protein. In MARK4L, the exon 16 is skipped, 
by alternative splicing causing a shift of the reading frame that changes the STOP codon generating the 
MARK4L protein, which possesses all the classical MARK domains. 
 
The MARK4 gene is ubiquitously expressed, with the highest levels in brain and testis (Beghini et 
al., 2003; Trinczek et al., 2004). The MARK4 sequence shows 55% homology with the other 
MARK proteins, with the highest homology with MARK3. Both MARK4 isoforms present the 
characteristic domain and protein structure of the MARK proteins, with the amino-terminal header, 
the catalytic domain, the UBA domain, the spacer region and the tail domain. The catalytic domain 
is the more conserved region among MARK proteins, with a 90% of sequence homology. This 
domain contains the three loops that are involved in the regulation and function of the protein, and 
in particular the T-loop that has the conserved sequence LDTFCGSP, with the two regulatory 
phosphorylation sites (T214 and S218). The spacer region is the less conserved sequence between 
the MARKs.  
As a consequence of alternative splicing, the two MARK4 isoforms differ in the C-terminal 
domain: MARK4L contains the KA1 as the other AMPK-related kinases, while MARK4S has a 
domain with no homology to any other known structure. MARK4 presents the lowest sequence 
homology in the tail region, as compared to MARK1-3 proteins. Nevertheless the prediction of 
secondary structure shows that this domain folds up in a conformation similar to those of MARK1, 
2 and 3, suggesting an analogous autoinhibitory function (Marx et al., 2010). 
 
3.2 MARK4 interactors 
By means of Tandem Purification Affinity and immunoprecipitation experiments 20 MARK4 
interacting proteins have been identified (Brajenovic et al., 2004). Among these, Cdc42 and PKCλ, 
that are components of the PAR-6 complex, have been involved in cell polarity. In addition 
MARK4 interacts with the transforming growth factor-β-induced anti-apoptotic factor, an ortholog 
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of Miranda, a centrosomal protein implicated in neuroblast asymmetric division in Drosophila 
(Mollinari et al., 2002).  
Many different 14-3-3 proteins have been identified to interact with MARK4 and in particular the 
14-3-3η. As previously mentioned, 14-3-3 proteins are involved in the regulation of several cellular 
process by binding phosphorylated proteins and has been proposed they could directly regulate 
MARK4 or act as bridging factors between several proteins acting in different pathways. Other 
MARK4 interactors appear to be associated with cytoskeleton, such as ARHGEF2, a microtubule-
associated exchange factor for Rho and Rac GTPases, and phosphatase 2A which has been involved 
in the regulation of tau (Sontag et al., 1999). In addition MARK4 co-precipitates in complex with α, 
β and γ tubulin, non-muscle myosin and actin (Trinczek et al., 2004). 
As previously reported MARK4 interacts and is regulated by LKB1 and aPKC kinases and the 
deubiquitinating enzyme USP9X (Brajenovic et al. 2004). 
 
3.3 Regulation of MARK4  
Given that the protein structure is conserved between MARK proteins, regulation of MARK4 is 
analogous to that of the other MARK members, and involves phosphorylation, ubiquitination and 
proteins interaction. 
MARK4 is activated by LKB1 and MARKK-induced phosphorylation of the conserved threonine 
residue (T214) in the activation loop (Brajenovic et al., 2004), whereas is inhibited by GSK3β 
phosphorylation of the S218 residue. 
Moreover it has been demonstrated that MARK4 is polyubiquitinated in vivo, and interacts and is 
deubiquitinated by the USP9X enzyme (Al-Hakim et al., 2008). The interaction between MARK4 
and USP9X was previously shown by tandem affinity purification and immunoprecipitation 
(Brajenovic et al., 2004). In the latter study, the role of the interplay between these two enzymes 
has been elucidated. In particular the USP9X silencing increases the polyubiquitination of MARK4, 
while the overexpression of USP9X prevents ubiquitination. The addition of ubiquitin chains does 
not control MARK4 stability, but rather may block the phosphorylation and activation by LKB1. 
MARK4 mutants that do not bind USP9X appear hyper-ubiquitinated and not phosphorylated at 
T214 in the T-loop. The proposed model suggests that when MARK4 is ubiquitinated, the ubiquitin 
chains might compete with the kinase domain for the UBA domain binding (that is necessary for the 
activation). Disruption of the interaction between the UBA and the Kinase domain destabilises the 
catalytic domain and thus blocks the phosphorylation by LKB1 (Figure 6) (Al-Hakim et al., 2008). 
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Figure 6. Model of the regulation of MARK4 phosphorylation by USP9X and ubiquitin (modified from Al-
Hakim et al., 2008). 
 
Otherwise polyubiquitin chains may cover sterically the T214 present in the T-loop or could cause 
conformational changes favouring the dephosphorylation by protein phosphatases (Al-Hakim et al., 
2008). 
It has also been demonstrated that MARK4 interacts with the aPKC, and as reported for MARK2 
and MARK3, might be phosphorylated and inhibited by this kinase (Brajenovic et al., 2004).  
 
3.4 MARK4 subcellular localisation 
It has been reported that exogenous GFP-conjugated MARK4 localises in normal and aberrant 
interphase centrosomes in CHO (Chinese Hamster Ovary) and neuroblastoma cell lines, a finding 
which is in contrast to the cytoplasmic localisation of the other members of the MARK family. It 
was also hypothesised that inactive MARK4 is located close to the nucleus, probably associated 
with the endoplasmic reticulum, and following activation it co-localises in centrosome to exert its 
functions (Trinczek et al., 2004). These results have been confirmed and expanded by our data 
obtained by immunofluorescence experiments with MARK4L specific antibody in glioma cell lines 
(Magnani et al., 2009). In particular it has been shown that endogenous MARK4L localises at 
normal and aberrant interphase centrosomes and maintains this association also in all the mitotic 
phases, co-localising with γ-tubulin throughout the entire cell cycle. The centrosome association 
was not abolished by nocodazole treatment, that induces microtubule depolymerisation, suggesting 
that MARK4L is a core component of centrosomes. Furthermore two novel MARK4L localisation 
sites have been identified, at the midbody during cytokinesis and in the nucleolus. All these results 
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were validated by immunoblotting experiments performed on centrosome, midbody and nucleolus 
fractions (Magnani et al., 2009). 
Recently we have demonstrated, by immunofluorescence experiments, that also the MARK4S 
isoform, localises at centrosomes and midbody, in glioma cell lines (Magnani et al., 2011). 
However, unlike MARK4L, the short isoform is not detectable in the nucleolus. Moreover in the 
same study we highlighted that the two isoforms are not present in the nucleolus of normal cell 
lines, including human normal neural progenitors, fibroblasts and myoblasts, but both are associated 
with the centrosomes and midbody, as observed in glioma cell lines. We also found that MARK4L 
is detectable in the nucleolus of glioblastoma-derived cancer stem cells, but not in normal neural 
stem cells. Therefore the nucleolar localisation appears to be a specific feature of MARK4L in 
transformed cells (Magnani et al., 2011). 
 
3.5 MARK4 in the central nervous system: potential role in gliomagenesis  
MARK4 is ubiquitously expressed, but elevated levels have been found in the brain, suggesting that 
MARK4 kinase may play important functions in this organ (Trinczek et al., 2004; Moroni et al., 
2006). The two isoforms are differentially expressed in the cells of the central nervous system 
(CNS), and their expression is regulated during neuron differentiation processes. In particular 
MARK4S is the prevalent isoform in human and mouse brain (Moroni et al., 2006), is not 
detectable in undifferentiated neural progenitors and neuroblastoma NT2 (NTera2) cells, but is up-
regulated during neuronal differentiation of both cell systems (Moroni et al., 2006). The short 
isoform was thus proposed to be a neuron-specific marker in the CNS. Conversely, MARK4L is 
present in undifferentiated progenitors and NT2 cells, and its expression is maintained at the same 
levels in differentiated neurons (Moroni et al., 2006). Indeed both MARK4 isoforms were found 
expressed in neurons by immunohistochemistry experiments, indicating that both proteins may play 
a role in neurons (Moroni et al. 2006). 
 
MARK4 gene maps at 19q13.2, a region frequently altered in glioma, the most common tumour of 
the CNS. By characterising the chromosomal rearrangements involving the 19q13 band in glioma, it 
has been found that MARK4 gene is duplicated in the Mi-4 glioblastoma (IV grade glioma) cell line 
(Beghini et al., 2003). Array-CGH analysis of 25 primary glioma cell lines confirmed the 
duplication in the Mi-4 cell line and revealed that MARK4 is included in a “gain” region in a few of 
the tested cell lines. In addition this experiment showed that MARK4 is never deleted in the 
analysed samples (Roversi et al., 2006), a finding intriguing as MARK4 maps close and marks the 
centromeric boundary of the LOH area observed in glioma (Hartmann et al., 2002). 
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In order to deepen the role of MARK4 in glioma, its expression has been extensively investigated 
using different approaches. By means of semi-quantitative PCR, MARK4L was found up-regulated 
in all the glioma samples analysed (8 tissue samples and 26 cell lines), with a direct correlation 
between MARK4L expression levels and malignancy grade. In addition MARK4L expression was 
found to be restricted to undifferentiated neural progenitor cells, while its expression was down-
regulated during glial differentiation. On the contrary MARK4S was found highly expressed in 
whole normal brain (showing low levels of MARK4L) and hardly detectable in glioma tissues and 
undifferentiated human neural progenitors. These results led to hypothesise that MARK4L might be 
a mitogen protein, important for proliferation and consequently highly enriched in proliferating or 
undifferentiated cells (Beghini et al., 2003).  
Recently we have demonstrated by parallel real-time PCR and immunoblotting experiments that 
both MARK4 isoforms are concurrently expressed in a set of 21 glioma cell lines and 36 glioma 
tissues of different malignancy grade. MARK4L is the predominant isoform, while MARK4S levels 
appear significantly decreased in comparison and have an inverse correlation with malignancy 
grade. MARK4S reduction attests a switch towards the expression of MARK4L and an associated 
loss of cell differentiation. Moreover also in glioblastoma derived cancer stem cells (GBM-CSC) 
and normal neural stem cells (NSC), MARK4L is the predominant isoform, whereas MARK4S is 
hardly detectable. Accordingly, immunohistochemistry experiments on both human and rodent 
tissues from adult and embryonic brain, showed that only MARK4L is expressed in the embryonic 
ventricular zone and adult sub-ventricular zone which are known sites of neural stem cells 
(Magnani et al., 2011). The subverted MARK4L/MARK4S ratio observed in GBM and GBM-CSC 
recapitulates the MARK4 expression profiling of NSC, with prevalence of MARK4L. The overall 
body of data suggested that the expression of the two MARK4 isoforms is tightly regulated during 
the proliferation/differentiation of neural stem cells and that changes in their expression levels may 
be a molecular marker of tumour transformation (Magnani et al., 2011).  
 
3.6 Potential role of MARK4 in Alzheimer’s disease  
Alzheimer’s Disease (AD), a multifactorial common disease with a small mendelian counterpart is 
one of the most investigated neurodegenerative disorders.  
One of the pathological hallmarks of AD is the hyperphosphorylation of tau, a microtubule 
associated protein, mainly expressed in the central nervous system. It has been demonstrated that 
hyperphosphorylated tau accumulates in the somato-dendritic compartments of neurons aggregating 
abnormally in paired helical filaments that form insoluble neurofibrillary tangles. As mentioned 
above, tau can be phosphorylated at Ser262 by MARK proteins, causing a reduction of the 
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microtubule-binding affinity and the consequent detachment from MTs. The unbounded tau can be 
subsequently phosphorylated by other kinases, including CDK5 and GSK3, leading to its altered 
localisation and cleavage (Chin et al., 2000; Gamblin et al., 2003; Drewes et al., 2004). In addition 
AD is characterised by other hallmarks including amyloid plaques, synapses defects and loss of 
neurons. Other studies have revalued MT alterations in AD, suggesting that phosphorylation of tau 
is not the initial event of the disease (Chatterjee et al., 2009) but a consequence of β-amyloid 
aggregation. It has been suggested that the abnormal β-amyloid might prime transport defects and 
improper distribution of tau into the somatodendritic compartments (Zempel et al., 2010) or 
alternatively that tau might be the major mediator of Aβ toxicity (Lewis et al., 2001; Gotz et al., 
2001; Rapport et al., 2002; Oddo et al., 2003). Many studies confirmed the involvement of MARK 
proteins in the development of Alzheimer’s disease and the central role of MARK4 in this 
pathology has been highlighted by three recent works.  
A genome-wide association study suggested a probable link between MARK4 and late onset 
Alzheimer’s disease (Seshadri et al., 2010). In addition it has recently been demonstrated that 
MARK4 has a more pronounced role, than other MARK proteins, in the pathological 
phosphorylation of tau in Alzheimer’s disease. It has been found that MARK4 expression and 
MARK4-tau interaction are more elevated in AD cases compared to control samples (Gu et al., 
2013). A merging evidence derives from another study which showed that MARK4 is a mediator of 
β-amyloid toxicity on synapses and dendritic spines. This study demonstrated that MARK4 
overexpression in rat hippocampal neurons led to tau hyperphosphorylation, reduced expression of 
synaptic markers, and loss of dendritic spines and synapses. The same alterations were obtained by 
treatment of neurons with β-amyloid oligomers. Interestingly the Aβ toxic effects could be 
abrogated by the inhibition of the endogenous MARK proteins, suggesting that these kinases might 
be the link between β-amyloid and tau pathology (Yu et al., 2012).  
 
3.7 Functions of MARK4 
MARK4 is the less characterised and studied member among MARK proteins, and more is known 
about its features that are universal to all members of the MARK family than features that are 
unique to MARK4, most of which remain to be elucidated. In particular many functions were 
ascribed to MARK4 based on its specific subcellular localisation and on the differential expression 
of its two isoforms in human tissues. Only recently, several works have demonstrated that this 
kinase is involved in the regulation of different processes, including spermatogenesis (Tang et al., 
2012), cell growth (Li & Guan 2012), ciliogenesis (Kuhns et al., 2013) and cell cycle (Rovina et al., 
submitted).  
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MARK4 and spermatogenesis. It has been reported that MARK4 is highly expressed in testis 
(Beghini et al., 2003; Trinczek et al., 2004), however its role in this tissue is still unknown. Insights 
on MARK4 localisation and possible functions in spermatogenesis came out from a recent study 
(Tang et al., 2012). Employing a rat testis model, it has been shown that MARK4 is expressed in 
both Sertoli and germ cells and is localised at the apical and basal ectoplasmic specialisation (ES) a 
testis-specific adherens junction, involved in the maintenance of cell polarity and adhesion (Tang et 
al., 2012). It has also been found that MARK4 expression is stage-specific during the epithelial 
cycle and strongly associated with the integrity of the apical ES. The authors hypothesised that 
MARK4 may regulate microtubules during spermatogenesis and given its localisation in ES close to 
actin filament bundles, may mediate the cross talk between microfilaments and microtubules (Tang 
et al., 2012).  
mTORC1 regulation. The mammalian target of rapamicin (mTOR) is a conserved kinase that is 
involved in the regulation of several cellular processes. This protein forms two distinct complexes, 
namely mTORC1 and mTORC2, the former implicated in cell growth, by inhibiting autophagy and 
stimulating protein synthesis (Wullschleger et al., 2006). Deregulation of mTORC1 complex 
contributes to many human diseases including cardiovascular, metabolic and autoimmunity 
disorders and cancer. Many extra and intra cellular signals, among which nutrients, energy levels, 
growth factors and stress conditions have been identified to regulate mTORC1. A recent study 
provided evidence on the role of MARK4 as negative regulator of mTORC1 based on the findings 
that MARK4 knockdown increased mTORC1 activity whereas MARK4 overexpression 
significantly blocked its activity (Li & Guan 2012). Interestingly, MARK4 was found to inhibit the 
activation of mTORC1 acting on Rag GTPases, which are implicated in amino acid signalling, but 
not to block the effect of Rheb, that directly interacts to activate mTORC1. It has been found that 
MARK4 also phosphorylates Raptor, a key component of the mTORC1 complex, and this 
phosphorylation interferes with the interaction between Raptor and Rag, which is important for the 
activation of mTORC1 (Li & Guan 2012). 
Ciliogenesis. The primary cilium is a microtubule-based structure that is involved in the 
coordination of important signalling pathways in both embryonic and adult tissues. The cilium is 
constituted by a microtubule core structure, the axoneme, surrounded by the ciliary membrane. The 
microtubules that form the axoneme are nucleated by the basal body, a structure derived from the 
mother centriole of the centrosome. The assembly of primary cilium starts at the G0/G1 phase of 
the cell cycle and then follows an ordered sequence of steps, that are regulated by different proteins. 
Involvement of MARK4 in ciliogenesis has been highlighted by a recent study demonstrating that 
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MARK4, which localises to the basal body of the primary cilium, is a positive regulator of the early 
steps of the process (Khuns et al., 2013). Indeed MARK4 knockdown leads to loss of primary cilia 
formation, impairing the initiation of axoneme elongation. It is also shown that MARK4 is involved 
in the regulation of the centrosomal localisation of ODF2 (outer dense fiber protein 2), a protein 
involved in ciliogenesis, as MARK4 depletion reduces centrosomal levels of ODF2, while 
overexpression prompted ODF2 accumulation in this compartment. Based on MARK4 interaction 
with ODF2 in vivo and MARK4 ability to phosphorylate ODF2 in vitro the authors conclude that 
MARK4 contributes to ciliogenesis acting on ODF2 and triggering its localisation in centrosomes 
(Khuns et al., 2013). 
The regulation of centrosome and cell cycle. It has been suggested that MARK4 could play a role 
in cell cycle progression, since localises at centrosome and midbody (Trinczek et al., 2004; 
Magnani et al., 2009; Magnani et al., 2011).  
By knockdown experiments on fibroblasts and glioma cell lines, we have recently demonstrated that 
MARK4 is implicated in the maintenance of cell morphology shaped by the cytoskeleton and is 
involved in the regulation of cell cycle, driven by ordered centrosome dynamics (Rovina et al., 
submitted).  
We have shown that silencing of MARK4S affects the morphology of both fibroblasts and glioma 
cells (G32). In particular fibroblasts lose their typical spindle-shaped morphology, appearing shorter 
and polygonal, while G32 cells lose their cell-cell interactions and appear rounded or abnormally 
stretched. Furthermore, proliferation of fibroblasts and G32 cells is severely reduced following 
MARK4S depletion, as indicated by the growth curves of interfered cells. By cytofluorimetric 
analysis we have demonstrated that MARK4S silenced cells are blocked in G1 phase, as the 
percentages of cells in S and G2/M phases are reduced and the percentage of cells in G1 phase is 
increased. In agreement with these observations we noticed that silenced cells display duplicated 
centrosomes, apical to the nucleus, a feature typical of the G/S phase transition, indicating that the 
centrosome cycle is altered and the cells are arrested in G1 phase. We thus hypothesised that 
MARK4 might be a crucial regulator of the G1/S checkpoint, and that critical levels of MARK4 are 
crucial for the proper functions of centrosome during cell cycle (Rovina et al., submitted). 
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4. Cytoskeleton, centrosomes, midbody and cell division 
4.1 Cytoskeleton 
The cytoplasm of eukaryotic cell is spatially organised by a network of protein filaments, which 
constitute the cytoskeleton. Cytoskeleton arrays build up complex structures that change during the 
cell cycle and between different cell types. This protein network providing the cell with shape, 
support and movement consists of three main structural components: microtubules, intermediate 
filaments and microfilaments (Table 2). 
 
Properties Microtubules Intermediate filaments Microfilaments 
Prototype proteins Tubulins Many, tissue-specific Actin 
Diameter (nm) 25 10-12 5-8 
Structure Conserved Diverse (with conserved subdomains) Conserved 
Expression Eukaryotes Absent from yeast Eukaryotes 
Solubility High Low High 
Polarity Yes No Yes 
Cellular location Cytoplasm Nucleus (laminin), cytoplasm (other) Cytoplasm 
Binding proteins Many Few Many 
Phosphorylation Limited Extensive Limited 
 
Table 2. Characteristics of the three major cytoskeletal structures (Modified from Omary et al., 2006). 
 
4.1.1 Microtubules 
Microtubules are crucial components of the cytoskeleton that play a main role in several cellular 
functions like cell migration and polarisation, intracellular transport, organisation of the 
intracellular space, chromosome segregation and cell division. 
Microtubules are complex hollow tubular structures, that are formed by the reversible association of 
heterodimers of α and β tubulin, arranged in a pseudo-helix of thirteen laterally associated linear 
protofilaments with a longitudinal seam (Lawson & Carazo Salas 2013). In most animal cells, MTs 
are nucleated at the centrosome, that acts as a MTOC (MT organizing Centre; see centrosome 
paragraph). Many different proteins are involved in their nucleation and organisation, among them 
the γ-tubulin associated with other proteins, forms a ring complex (γTuRC), onto which α and β 
tubulin dimers are added to build a microtubule. Hence MT appear to be polarised with a minus-end 
capped and anchored at the MTOC and a plus-end usually localised at the cell periphery (Forges et 
al., 2012). Microtubules stochastically alternate between phases of growth (polymerisation), pause 
and shrinkage (depolymerisation) separated by rescue (transition from shrinkage to growth phase) 
or catastrophe (transition between growth phase and shrinkage) events (Figure 7). This dynamic 
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behaviour, called “dynamic instability”, permits sampling of the three-dimensional space, 
consenting microtubules to efficiently capture cellular targets, like mitotic kinetochores (Mitchison 
& Kirschner 1984; Hayles & Nurse 2001). Dynamic instability is regulated by binding, hydrolysis 
and exchange of GTP by β-tubulin. During MTs polymerisation heterodimers of GTP-bound 
tubulin are added at the plus-end. A slight delay between polymerisation and GTP hydrolysis by β-
tubulin forms a GTP-tubulin cap. Loss of this cap induces a quick depolymerisation (Drechsel & 
Kirschner 1994). 
 
Figure 7. Schematic view of microtubule dynamics and regulation. Microtubules stochastically alternate 
between phases of growth, pause and shrinkage (Modified from Forges et al. 2012).  
 
This dynamic behaviour is fundamental for the important functions played by MTs and is highly 
regulated by multiple factors. In particular microtubule dynamics are controlled by a balance 
between the activity of different microtubule-stabilising and destabilising factors, that work by 
altering microtubule integrity, especially at the plus-end, thereby regulating indirectly microtubule 
length.  
Among stabilising proteins two classes have been identified: the classical microtubule associated 
proteins (MAPs), that permeate the microtubules lattice and the plus-end tracking proteins (+TIPs), 
that act through specific interactions with the plus end (Amos & Schlieper 2005). The MAPs are 
proteins that bind to and stabilise microtubules. Different parts of these proteins interact with the 
luminal and external tubule face, therefore they probably co-assemble during polymerisation and 
act from within. The MAP family includes tau and MAP2 that are strongly expressed in neurons 
and MAP4 which is present in all non-neuronal cells. All these proteins have a conserved protein 
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structure with an N-terminal projection domain, which extends from the microtubule surface and 
may affect MT spacing and cytoplasmic transport, and a C-terminal microtubule binding domain 
that contains a proline-rich sequence and the KGXS motif which is phosphorylated by MARK 
proteins (Drewes et al., 1998).  
+TIPs normally accumulate at polymerising plus-end and undergo repeated cycles of association 
and dissociation, and dynamically track the growing plus-end. In addition to the regulation of MT 
dynamics, they are involved in the interactions of microtubules with chromosomes during mitosis 
and with the cellular cortex. 
Many different proteins have been identified to have destabilising effect on MTs, either by cutting 
microtubules (for example katanin and spastin) or by inducing depolymerisation (Lawson & Carazo 
Salas 2013). 
As post-translational modifications of tubulin are also linked to the regulation of MT dynamics, 
these modifications seem to establish a readable code for MAPs and motors (Janke & Kneussel 
2010). Microtubule modifications such as glutamylation, detyrosination, acetylation and glycylation 
are almost all carried out on polymerised tubulin, and they are mostly linked to MT stability. 
All these regulation systems are necessary for the microtubule functions in the cells. Indeed 
microtubules play a crucial role in different cell processes including cell architecture and motility, 
they give shape to cells, organise the intracellular space, serve as intracellular transport tracks, and 
are key component in important cellular structures like axonemes and mitotic spindle. 
 
4.1.2 Intermediate filaments 
Intermediate filaments are the least studied and understood of the three cytoskeletal systems that are 
present in all vertebrate cells. They are constituted by subunits that form 10-12 nm filaments, of 
intermediate size compared with the two other cytoskeletal components (microfilaments 5-8 nm, 
microtubules 25 nm). Despite the structure of these filaments is maintained, the protein 
compositions is not conserved, as they are encoded by ~75 different genes (Goldman et al., 2012). 
In addition the transcription of these genes is regulated during development, and they are expressed 
in cell-, tissue- and differentiation-specific fashions. Based on domain and sequence homology, 
intermediate filament proteins have been classified into five groups (Table 3).  
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Intermediate filament (name) Type Size (kDa) Cell or tissue distribution 
Cytoplasmic    
Keratins (K9-K20) I 40-64 Epithelia (hair Ha 1-8) 
Keratins (K1-K8) II 52-68 Epithelia (hair Hb 1-6) 
Vimentin III 55 Mesenchymal 
Desmin III 53 All muscle 
GFAP III 52 Astrocytes 
Peripherin III 54 Peripheral neurons 
Syncoilin III 54 Muscle (mainly skeletal/cardiac) 
Neurofilament-L IV 61 Central and peripheral neurons 
Neurofilament-M IV 90 Central and peripheral neurons 
Neurofilament-H IV 110 Central and peripheral neurons 
α-Internexin IV 61 Central neurons 
Nestin IV 240 Neuroepithelia 
Synemin IV 180 (α), 150 (β) All muscle 
Nuclear    
Lamins A/C V 62-78 Nuclear lamina 
Lamins B1, B2 V 62-78 Nuclear lamina 
Other    
Phakinin (CP49) Orphan 46 Lens fibre cells 
Filensin Orphan 83 Lens fibre cells 
 
Table 3. Features of intermediate filaments proteins. 
 
All intermediate filament proteins show a similar structure as they consist of a central coil-coil α-
helical road domain, that is flanked by a non-α-helical N-terminal head and a C-terminal domain of 
different lengths (Figure 8). The road domain is subdivided into coil 1 (subdomains 1A and 1B) and 
coil 2 (subdomains 2A and 2B), which are interrupted by a non-α-helical linker. Intermediate 
filaments assemble from a coiled-coiled dimer, and the responsible region is the highly conserved, 
α-helix central road domain. These dimers associate in a hierarchical fashion to produce 
intermediate filaments. Some intermediate filament proteins form homopolymeric filaments (for 
example vimentin and desmin), whereas others are obligate non-covalent heteropolymers (e.g. 
keratins and neurofilaments) (Toivola et al., 2005). 
 
 
Figure 8. Schematic illustration of intermediate filaments protein domain. All members of the intermediate 
filament family present a similar structure with a central coil-coil α-helical road domain, flanked by a non-α-
helical N-terminal head and a C-terminal domain. 
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The regulation of intermediate filaments mainly involves post-translational modifications and 
binding proteins. The principal post-translational modifications include phosphorylation, 
glycosylation (within head/tail domain) and transglutamination. Phosphorylation, the best studied of 
the post-translational modifications, takes a central role for their regulation; by contrast the 
regulation of microtubules and microfilaments occurs primary via their associated proteins. The 
phosphorylation typically involves multiple Ser/Thr residues, preferentially within the head and tail 
domains. Phosphorylation and dephosphorylation are crucial for the regulation of intermediate 
filament dynamics primarily by modifying their intrinsic properties including solubility, 
conformation and filament organisation, and, additionally, by regulating other post-translational 
modifications (Omary et al. 2006). 
In addition to post-translational modifications, caspase-mediated proteolysis is another mechanism 
involved in the regulation of intermediate filaments. In particular, caspase-cleavage primarily takes 
place at a conserved motif within the linker region.  
Finally many different intermediate filament-associated proteins have been identified, including 
kinases, phosphatases, cytoskeletal linker proteins, adaptor proteins and junctional proteins. These 
proteins can regulate or be regulated by intermediate filaments. 
 Intermediate filaments exhibit many different mechanical and non-mechanical functions. The 
principal role of intermediate filaments is structural, as they are involved in the maintenance of the 
shape and in the protection of cells from mechanical and non-mechanical stresses (for example 
oxidative injury). More recent studies have demonstrated that intermediate filaments are also 
expressed in the leading edge of cells and are essential for cell polarity and migration. In addition to 
these well-established functions, intermediate filaments play a role in the regulation of the protein 
targeting and organelle functions, contributing to subcellular organisation, organelle shape and 
mechanical stability and have been also associated to the modulation of protein (Toivola et al. 
2005)  
Among the big protein family of intermediate filaments, vimentin is one of the most familiar 
members, as it is the main intermediate filament protein in mesenchymal cells and is a 
developmental marker of cells and tissues.  
Vimentin interacts, directly or indirectly, with many different cell structures including plasma 
membrane, lipid components, Golgi, nucleus, lysosomes, microtubules and microfilaments, 
supporting its involvement in multiple cellular processes. For example vimentin plays an important 
role in cell adhesion, by regulating integrin functions. On the other hand it has a key role in the 
lymphocyte attachment to vascular endothelium and in the transcellular migration through 
endothelial cells (Nieminen et al. 2006).  
32 
 
Several studies have demonstrated the link between vimentin and signal transduction and, due to the 
high number of vimentin interactors, it has been proposed that vimentin, acting as a binding 
platform and scaffold for signalling elements working in the same regulatory pathway, could 
modulate the transduction of the signal (Pallari & Eriksson 2006).  
 
4.1.3 Microfilaments 
Microfilaments are the smallest component of the cytoskeleton, and are constituted by actin 
filaments and associated proteins. Actin is one of the most abundant and conserved proteins present 
in eukaryotic cells and can be subdivided in three broad classes: α-, β- and γ-actins.  
Actin is mainly present in the cytoplasm, and can be found in both monomeric (G-actin, globular-
actin) and polymerised (F-actin, filamentous-actin) form. The G-actin molecule is constituted by a 
single polypeptide chain of 375 amino acid residues (~ 42kDa), that folds into two equally sized 
domains divided by a deep cleft that harbours a binding pocket for small molecules like nucleotides 
(ATP) (Michelot & Drubin 2011). 
Actin undergoes cycles of polymerisation and disassembly between the globular and the 
filamentous form, that is the prevalent form in the eukaryotic cytoplasm. The polymerisation 
process can be essentially divided into three main phases: 1) a slow initial association to a dimer 
that is more prone to quickly dissociate into monomers than to assemble; 2) the formation of a 
stable trimer that is the nucleus of polymerisation; and 3) the elongation phase in which actin 
monomers are rapidly assembled (Dos Remedios et al. 2003). As the initial polymerisation is 
kinetically unfavourable, cells need additional factors, namely actin filament nucleators (for 
example Arp2/3 complex), that stabilise dimer formation. Actin filaments assemble as a right-
handed, double-stranded helices, and appear very dynamic (Schoenenberger et al. 2011). Two 
components are essential for the dynamic behaviour of these filaments: the intrinsic asymmetry of 
the G-actin subunit and the interaction with actin binding proteins. The structural polarity of the 
subunits and the rapid polymerisation of ATP-charged monomers combined with the slow ATPase 
activity of actin, lead to filaments with a fast growing end (called barbed end) and a slow growing 
end (namely pointed end). Consumption of ATP-actin at the barbed end results in a critical level of 
subunits where extra ATP-actin addition is balanced by the loss of ADP-actin at the pointed end. 
This sequence of events leads to filaments of constant length but with a dynamic nature, as the 
subunits travel from the fast growing to the slow growing end, a process called “treadmilling” 
(Wegner 1976). In cells treadmilling is strongly controlled by different protein ligands, that can 
interact with either end of the filament, and can facilitate or block the elongation and stability of 
actin filaments (Schoenenberger et al. 2011). 
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The intrinsic asymmetry of actin and its interaction with different ligand proteins explain the 
dynamic of actin filaments, that are involved in many different vital processes. Actin filaments, in 
cells, are not found as disorganised meshwork, but as organised assemblies localised in specific 
regions of the cytoplasm where they can execute their functions. In particular they are involved in 
the regulation of fundamental processes including cell shape (filamentous actin forms a cortical web 
that underlines plasma membrane), cell motility and migration (lamellipodia and filopodia are built 
of actin filaments), vesicular movement, phagocytosis, cytokinesis and molecular transport between 
the plasma membrane and the nucleus. 
 
4.2 Centrosomes 
The centrosome is a small non-membranous organelle, normally positioned centrally in the cell, 
close to the nucleus (Fukasawa 2002). It is considered the primary microtubule-organising centre 
(MTOC) in animal cells, as it can regulate nucleation and spatial organisation of microtubules 
(Bettencourt-Dias & Glover 2007).  
Centrosomes consist of two distinct domains (Figure 9): 
 the centriolar domain that includes the two centrioles, namely mother and daughter, which 
are cylindrical organelles consisting of nine microtubule triplet structures. The mother 
centriole presents subdistal and distal appendages, that dock cytoplasmic microtubules; 
 the pericentriolar domain, an electron-dense matrix called pericentriolar material (PMC), 
consisting of many fibres and proteins that surround the centrioles. The PMC is a crucial 
structure that anchors and nucleates cytoplasmic microtubules during interphase and 
mitosis, by associating α and β tubulin dimers from a γ-tubulin ring. 
 
 
Figure 9. Structure of the centrosome. Centrosomes are constituted of two centrioles enclosed by an 
electron-dense matrix, the pericentriolar material (Modified from Bettencourt-Dias & Glover 2007). 
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The centrosomes have many different functions during interphases and mitosis. As above 
mentioned, centrosome controls the nucleation and organisation of the microtubule network, and so 
it is involved in the regulation of several processes including cell adhesion, polarity and motility in 
interphase, and spindle pole organisation and chromosome segregation during mitosis. The ability 
of the centrosome to organise the microtubule network depends on its capacity to nucleate, anchor 
and release microtubules. The PCM is a key structure, containing many different regulatory 
components, such as γ-tubulin. The changes in the microtubule-nucleating capacity during the cell 
cycle, seem to be directed by a balance of factors that limit or promote the recruitment of MT-
organising molecules.  
It has been proposed that centrosomes can also act as signalling platforms because they host 
different regulatory complexes, including checkpoint and tumour suppressor proteins (Doxsey et 
al., 2005a). In addition centrosomes might play a role in cell cycle regulation, and in particular they 
may regulate the G1/S transition and the cytokinesis (Doxsey et al., 2005b).  
The number of centrosomes is tightly regulated and, similarly to the genome, is intimately coupled 
to the cell cycle. Centrosome duplicates only once in the cell cycle, during G1/S transition and in S 
phase, to ensure the formation of a bipolar spindle in mitosis. 
Centrosomes that are aberrant in size, shape, composition (also with improper phosphorylation or 
expression of centrosomal proteins) or number are frequently observed in many tumours 
(Yamamoto et al., 2004; Kastsetos et al., 2006). A surplus of centrosomes can lead to the formation 
of aberrant multipolar mitotic spindles, which can be responsible for chromosomes mis-segregation 
and, consequently, for the chromosomal instability (CIN) often found in tumours (Ganem et al., 
2009). 
 
4.3 Cytokinesis and Midbody 
Cytokinesis occurs at the very end of mitosis and is the process that leads to physical division of a 
single cell (mother cell) into two daughter cells. This event implicates the accurate coordination of 
independent pathways involved in the regulation of cell cycle, microtubules, actin, membrane and 
organelle dynamics. 
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Figure 10. Schematic representation of the progression through cytokinesis (Modified from Steigemann & 
Gerlich 2009) 
 
Cell division follows a well-ordered progression of steps, in which mitosis is the first (Figure 10). 
During mitosis the mother cell forms the mitotic spindle, consisting of two microtubule asters 
located at the cell poles, that allows the equal segregation of chromosomes into the daughter cells. 
During anaphase, after sister chromosomes have been separated, the residual non-kinetochore 
overlapping microtubules, form a structure called spindle midzone. Together with the spindle asters, 
the central spindle, present in the midzone establishes the position of the actomyosin ring, that 
initiates to assemble and contract. At this stage, the post-mitotic sister cells remain connected by an 
intracellular bridge, and the remnant of the spindle midzone persists as a structure called midbody 
(Mullins & Biesele 1977; Mullins & McIntosh 1982). This structure is constituted by overlapping 
antiparallel bundles of microtubules surrounded by an electron-dense matrix of proteins. The 
microtubules present in the midbody are acetylated (a post-translational modification associated 
with stable microtubules) and resistant to different perturbations, including depolymerisation drugs. 
However, it has been demonstrated a permanent growth of microtubules both inwards and outwards 
from the midbody, indicating that midbody MTs are less stationary than initially thought 
(Steigemann & Gerlich 2009).  
The midbody provides an anchor for the cleavage furrow, which will divide the mother cell inside 
the midzone, in a point which is equidistant from the two asters. In this furrow, the contractile acto-
myosin ring grows up and shrinks, producing the “stricture” of the cell, until the two opposing 
membrane surfaces come in contact and merge, closing and delimiting the two daughter cells. 
Coinciding with abscission, the midbody MT-bundles adjacent to one side of the midbody 
brusquely disassemble. Notwithstanding midbody MT-bundles lateral to the midbody disassemble 
during abscission, they remain stable at their overlap region, which can persist as remnant 
throughout multiple cell cycles in some cell types (Gromley et al., 2005), while in others it is 
degraded by autophagy (Pohl & Jentsch 2009).  
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It has been suggested that the midbody might play an important role in the cytokinesis and in 
particular it might be involved in preserving a bipolar spindle and in correctly separating the 
cytoplasm between the daughter cells. 
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1. Cell Cultures 
1.1 Primary Glioma Cell Lines 
The oligoastrocytoma (G157) and glioblastoma (G32) cell lines used in the present study were 
selected from a panel of 21 human primary glioma cell lines, that were obtained from post-surgery 
specimens and characterised as described elsewhere (Magnani et al., 1994; Perego et al., 1994; 
Beghini et al., 2003; Roversi et al., 2006). In Table 1 are reported the features of the two selected 
cell lines. 
 
Cell 
line 
Sex/Age at 
surgery 
Histological diagnosis 
WHO 
grade 
Karyotype 
G157 M / 31 Oligoastrocytoma II not evaluated 
G32 M / 63 Glioblastoma IV 
64, XXY, +1, +7, +7, +8, +8, +10, +13, +14, 
+14, +18, +19, +21, +22, +3mar 
 
Table 1. Clinic and karyotypic features of the gliomas from which the cell lines derive. 
 
Both glioma cell lines were grown in RPMI supplemented with 5% foetal bovine serum (FBS), 100 
U/ml penicillin and 100 U/ml streptomycin at 37°C and 5% CO2. Before reaching confluence, 
during exponential growth phase cells were detached using trypsin-EDTA (0.05%) and split. To 
verify the absence of mycoplasma contamination cells were analysed by immunofluorescence with 
DAPI. 
 
1.2 Normal Human Fibroblasts 
Normal human adult fibroblasts were grown at 37°C in a 5% CO2 atmosphere in RPMI 
supplemented with 10% FBS and 100 U/ml Penicillin-Streptomycin. Fibroblasts were obtained 
from “Cell Line and DNA Biobank from Patients Affected by Genetic Diseases” (G. Gaslini 
Institute, Genoa). 
 
1.3 Human Embryonic Kidney 293T cell line 
Human Embryonic Kidney 293T (HEK293T) cells were grown in DMEM high glucose, 
supplemented with 10% FBS and 100 U/ml Penicillin-Streptomycin, at 37°C in a 5% CO2 
atmosphere. The absence of mycoplasma was confirmed by immunofluorescence with DAPI. 
  
 
 
39 
 
2. Flow Cytometry analysis 
Flow cytometry is a technology that allows to measure and then analyse multiple physical 
properties of single particles, generally cells, as they flow in a fluid stream through a ray of light. 
The characteristics that can be analysed include particle’s relative size, relative granularity or 
internal complexity and relative fluorescence intensity. These properties are determined by an 
optical-to-electronic coupling system that registers how the cell scatters incident light and emits 
fluorescence. 
A flow cytometer is composed of three main systems (Figure 1): 
 the fluidics system, that transports particles in a fluid stream to the laser beam for 
interrogation; 
 the optics system, that consists of lasers to illuminate the particles and optical filters to 
direct the arising light signals to the detectors; 
 the electronics system, that converts detected light signals into electronic signals, which can 
be processed by computer.  
 
 
Figure 1. Schematic representation of a typical flow cytometer setup (Modified from Rahman M – 
Introduction to Flow Cytometry) 
 
When a sample is injected into flow cytometer, the particles are causally distributed in three-
dimensional space. To be properly interrogated by the detection system, the sample must be 
ordered, by the fluidics system, into a stream of single particles: a central channel, through which 
the sample is injected, is surrounded by an outer sheath of faster flowing fluid that accelerates the 
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particles and confines them to the centre of the sample core. This process, known as hydrodynamic 
focusing, creates a single file of particles which can be analysed by passing through one or more 
beams of light.  
When particles pass through a laser beam they deflect the incident light causing its scattering. The 
extent to which this occurs depends on the physical properties of the particle. Forward-scattered 
light (FSC) is proportional to cell-surface area and is a measurement of the mostly diffracted light 
that is detected just off the axis of the incident light beam in the forward direction by a photodiode. 
Side-scattered light (SSC) is a measurement of mostly refracted and reflected light and is collected 
at 90° to the laser beam. SSC is related to the internal complexity and cell granularity.  
Both FSC and SSC are unique for each particle and a correlated measurement of the two can be 
used to distinguish different cell types in a heterogeneous sample. 
Fluorescence measurements can provide qualitative and quantitative information about 
fluorochrome-labeled cell molecules. In particular different molecules including cell surface 
receptor or specific intracellular proteins, can be highlighted using fluorescent ligand or 
polyclonal/monoclonal antibodies labelled with fluorochromes. Other substances such as DNA and 
RNA, can be stained with fluorochromes that bind to them in a stoichiometric manner.  
Flow cytometers use distinct fluorescence channels to detect light emitted, and the number of 
detectors will vary according to the instrument and its manufacturer. Once a cell flows through the 
laser light, the emitted SSC and fluorescence are diverted to photomultiplier tubes while a 
photodiode collects the FSC. All of the signals are focused to their specific detectors via a system of 
optical filters and mirrors. The filters block light by absorption and can be classified in three major 
types: 
 long pass filters, that transmit wavelengths equal to or longer than a definite wavelength; 
 short pass filters, that transmit light wavelengths equal to or shorter than a specified 
wavelength; 
 band pass filters, that transmit light within a specified narrow range of wavelengths.  
Dichroic mirrors are devices that direct light of different wavelengths in diverse directions. In 
particular they allow the passage of the specified wavelengths in the forward direction and deflect at 
90° angle the blocked light. 
When light signals hit a side of photodetector, they are converted in a proportional number of 
electrons that are amplified to create a greater electrical current that is then converted to a voltage 
pulse. The measurement from every detectors is referred to as a “parameter” (for example FSC, 
SSC or fluorescence), and the data acquired in each parameter are known as “events” and represent 
the number of cells showing the physical feature or marker of interest. 
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Flow cytometers are paired with a computer for data acquisition and analyses, with the possibility to 
measure several parameters simultaneously and a graphical output known as “cytogram”. The 
operator can establish a threshold value and define an “electronic gate”, to exclude irrelevant events 
(for example debris) or to select the cell population of interest. 
The flow cytometry has many different application in cell biology including: absolute cell count, 
recognition of particular cell population, viability and apoptosis, differentiation and cell cycle 
distribution (Rahman M – Introduction to Flow Cytometry; Introduction to Flow Cytometry: A 
Learning Guide, BD Biosciences). 
 
2.1 Evaluation of MARK4L and MARK4S expression during cell cycle 
The evaluation of MARK4 isoforms expression during cell cycle phases was performed using flow 
cytometry, on cells stained with specific MARK4 antibodies and propidium iodide (PI) for DNA 
counterstaining. 
 
Sample preparations 
Cells were harvested using trypsin/EDTA 0.05%, counted and washed with cold PBS. The pellet 
was then accurately resuspended in 1 ml of Saline GM solution on ice using 21G needle and 
syringe. To fix cells preventing aggregation, 3 ml of cold 96% methanol were added dropwise while 
the suspension was vortexed.  
 
Saline GM solution 
Glucose 1.1 g/l 
NaCl 8.0 g/l 
KCl 0.4 g/l 
Na2HPO4•2H2O 0.2 g/l 
KH2PO4 0.15 g/l 
EDTA 0.2 g/l  
 
 
MARK4L and MARK4S – DNA staining  
To evaluate MARK4L and MARK4S expression during the cell cycle, fixed samples were washed 
three times with PBS and permeabilised with PBS containing 0.1% Triton X-100 for 7 min on ice. 
After three washes with PBS, cells were incubated with PBS containing 5% BSA and 0.1% Tween 
20 for 15 min on ice, to block non-specific binding. After one wash with PBS cells were incubated 
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with anti-MARK4L (GenScript Corporation, Piscataway, NJ, USA) or anti-MARK4S (ab5262; 
Abcam, Cambridge, UK) antibodies diluted 1:100 in 400 μl PBS containing 0.1% Tween 20 
overnight at 4°C. Cells were washed with PBS and then incubated with FITC-conjugated anti-rabbit 
(Sigma, Saint Louis, MI, USA) or Alexa488-conjugated anti-goat (Invitrogen, Paisley, UK) 
antibodies diluted 1:200 in PBS containing 0.1% Tween 20 for 1 hour at room temperature. Cells 
were washed with PBS, and then incubated with 1 ml of PBS containing propidium iodide (PI) 2.5 
μg/ml and 25 μl RNAse A (1mg/ml) overnight at 4°C before the analysis with cytofluorimeter. The 
fluorescence intensity of cells stained with PI correlates with the DNA amount: given that DNA 
content duplicates during S phase, it is possible to distinguish G0/G1, S and G2/M. 
Cytofluorimetric analysis was performed using FACS-Calibur flow cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA), and fluorescence pulses were detected using a laser beam at 488 nm and 
a band pass filter at 530 ± 30 nm for anti-MARK4L or MARK4S green fluorescence and 620 ± 35 
nm for DNA content analysis. For each samples 10000 events were acquired. 
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3. RNAi 
To knockdown MARK4S in fibroblast cells, we performed RNAi using Stealth RNAi™ siRNA 
duplexes (Invitrogen), transfected by lipid-mediated transfection with Lipofectamine™ RNAiMAX 
(Invitrogen). Stealth siRNA used in silencing experiments is customised siRNA, designed to 
specifically target exon 16, skipped in MARK4L, and thus able to determine specific MARK4S 
silencing. The sequence of MARK4S siRNA is reported in Table 2. 
 
 
siRNA Sense Antisense 
Target 
Exon 
Stealth 
siRNA #10 
CGAUCCCUCUAAACGGCAGAACUCU AGAGUUCUGCCGUUUAGAGGGAUCG 16 
 
Table 2. Sequence of MARK4S siRNA  
 
 
siRNA negative control (siRNA#1, Ambion, Paisley, UK), not targeting any specific gene product 
(because designed to have no similarity to human transcript) was used to distinguish non-specific 
(NS) effects on siRNA treated cells. 
 
 
Based on previous experiments, we performed knockdown with the following time table: 
 Day 0: Reverse transfection; 
 Day 2: Forward transfection; 
 Day 3: analysis of siRNA effects. 
 
 
In reverse protocol, transfection mix is prepared and then dispensed in each plate and only after, 
cells and medium are dispensed. In forward transfection the mix is generally prepared and added the 
day after the plating of cells.  
RNAi duplex-Lipofectamine RNAiMAX complex were prepared as follow. RNAi duplexes were 
diluted in RPMI Medium without serum and antibiotics to attain the optimal final concentration. 
After mixing, Lipofectamine RNAiMAX was added to the mix, incubated for 20 minutes at room 
temperature and then dispensed in each plate. Cells, diluted in RPMI with 10% FBS without 
antibiotics were added to the plates and then incubated at 37°C 5% CO2 for 48 hours, before the 
forward transfection.  
In forward transfection the mix was prepared and incubated as above described for reverse protocol. 
The same plates used for reverse transfection were treated after 48 hours as follows. Culture 
medium was removed and correspondent amount of transfection mix (Table 3) was added to each 
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plate. RPMI with 10% FBS without antibiotics was added to each plate, then incubated at 37°C 5% 
CO2 until ready to assay for gene knockdown. 
 
Culture 
Vessel 
Transfection 
mix Volume 
siRNA 
concentration 
Lipofectamine 
RNAiMAX 
Reverse transfection 
Forward 
transfection 
Cell 
Number 
Cell 
suspension 
Culture 
medium 
35 mm 500 µl 60 nM 5 µl 100,000 2 ml 2 ml 
100 mm 1,000 µl 60 nM 10 µl 600,000 8 ml 8 ml 
 
Table 3. Cell number and concentration of reagents used for reverse and forward transfection. 
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4. Overexpression studies 
MARK4L and MARK4S overexpression studies were carried out in normal human fibroblasts and 
in the oligoastrocytoma G157 cell line, using different plasmids containing wild type 
MARK4L/MARK4S or the kinase dead (KD) mutants. In addition we used plasmid with only GFP 
as negative control to discriminate the non-specific effects due to transfection and overexpression. 
 
4.1 Plasmid construction 
 
Total mRNA from the ReNcellCX cell line was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) with 
random examers, according to the manufacturer’s protocol.  
Full-length MARK4L open reading frame was amplified by PCR from this cDNA using Pfu DNA 
polymerase (Promega, Madison,WI, USA) and MARK4L specific primers also harbouring BamHI 
and EcoRI restriction site (Forward primer 5’-GTACCTAGGATCCTGTCTTCGCGG-3’ and 
reverse primer 5’-GATGATGAATTCGGTGGCTCAGAG-3’). The following conditions were 
used: 
 
10x Buffer 5 µl  
dNTP mix (10 mM) 1,2 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Pfu polymerase  1 µl 
cDNA 2 µl 
H2O to 50 µl 
 
Full-length MARK4S cDNA was PCR-amplified from the cDNA clone OCABo5050C0222D 
(Source BioScience, Cambridge, UK) by means of Pfu DNA polymerase (Promega) and MARK4S 
specific primer also harbouring BglII and EcoRI restriction site (Forward primer 5’-
TACCTAAGATCTTGTCTTCGCGG-3’ and reverse primer 5’-
GTTGATGAATTCGCCCTACACTCC-3’). We used the following conditions: 
 
10x Buffer 5 µl 
 
dNTP mix (10 mM) 1,2 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Pfu polymerase  1 µl 
cDNA 2 µl 
H2O to 50 µl 
 
MARK4L and MARK4S cDNA were then digested, purified and cloned into the BamHI/EcoRI site 
of the mammalian plasmid pcDNA4/HisMax (Invitrogen), a vector that includes a cleavable N-
terminal Xpress™ tag for the detection of the recombinant protein with mouse anti-Xpress™ 
antibody (Invitrogen). 
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MARK4 cDNA and 500 ng of vector were digested in parallel, to make compatible ends, with 
BamHI/EcoRI or BglII/EcoRI restriction enzymes for MARK4L and MARK4S respectively. 
Following purification the insert was joined into plasmid using T4 DNA ligase (Promega). E. coli 
DH5α cells were chemically transformed with the recombinant DNA construct and then plated onto 
LB agar plate containing 100 µg/ml of ampicillin, in order to select the transformed bacterial cells. 
MARK4L and MARK4S cDNAs were also sub-cloned into pAcGFP1-C2 (Clontech, Mountain 
View, California USA) to obtain GFP-MARK4L and GFP-MARK4S constructs, respectively, using 
the protocol above described. 
 
4.2 Mutagenesis of MARK4L and MARK4S vectors 
The Thr214 and Ser218 are phosphorylation sites that are important for the activation and 
regulation of the MARK4 protein isoforms. To obtain catalytically inactive forms of MARK4L and 
MARK4S we mutated both the Thr214 and Ser218 into alanine, using QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies Inc., Santa Clara, CA, USA) according to 
manufacturer’s instruction. This technique is performed using a high-fidelity DNA polymerase for 
mutagenic primer-directed replication of both plasmid strands to obtain mutated vectors. The 
procedure can be divided in three steps: 
1. Extension of oligonucleotide primers (each complementary to opposite strands of the 
plasmid) during temperature cycling to produce the mutated vectors.  
2. Digestion of the parental template using a specific endonuclease that recognises 
hemimethylated and methylated DNA. 
3. Bacterial transformation with the mutated plasmid. 
 
For MARK4L and MARK4S mutation we mutagenized the pAcGFP1-C2 MARK4L/MARK4S 
using the following primers: 
 Forward primer: 5’-TCGAAGCTGGACGCCTTCTGCGGGGCCCCCCCTTATGCCGCCCCG-3’ 
 Reverse primer: 5’-CGGGGCGGCATAAGGGGGGGCCCCGCAGAAGGCGTCCAGCTTCGA-3’ 
The reaction mix was prepared and then cycled according to this protocol: 
 
10x reaction buffer 5 µl  
dsDNA template  10 ng  
Forward primer 125 ng 
Reverse primer 125 ng 
dNTP mix 1 µl 
QuikSolution 3 µl 
PfuUltra HF DNA polymerase 1 µl 
H2O to 50 µl 
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We then added 1µl of Dpn I restriction enzyme directly to each amplification reaction, mixed by 
pipetting the solution up and down and then incubated at 37°C for 1 hour to digest parental DNA. 
Following this step, XL10-Gold ultracompetent cells were chemically transformed and then were 
plated onto LB agar supplemented with 50 µg/ml of Kanamycin, in order to select the bacteria that 
incorporated the mutagenized vector. 
 
4.3 Plasmid extraction and sequence analysis. 
Transformed bacteria, containing the plasmid, were grown overnight at 37°C in 3 ml or 50 ml of LB 
supplemented with the appropriate antibiotic (Ampicillin or Kanamycin). Plasmid were then 
extracted using PureYield™ Plasmid Miniprep System or PureYield™ Plasmid Midiprep System 
(Promega) according to the manufacturer’s instructions.  
Plasmid quantity and quality were determined by measuring absorbance at 230, 260 and 280 nm 
with the ND-1000 Spectrophotometer (NanoDrop products, Waltham, MA, USA, by Thermo Fisher 
Scientific, Inc.). 
To confirm that MARK4L or MARK4S cDNA was correctly oriented in frame with the fusion tag 
and without sequence variations, all the generated plasmids were sequenced. 
 
4.4 Transfection of Fibroblasts  
Fibroblasts were transfected by lipid-mediated transfection with Lipofectamine™ LTX & plus 
reagents (Invitrogen), according to manufacturer’s instructions. Briefly, one day before transfection, 
cell were plated at the appropriated concentration in RPMI with 10% FBS without antibiotics. The 
day of transfection we prepared plasmid-Lipofectamine™ LTX complex as follows: plasmid DNA 
was diluted into Opti-MEM
®
 I Reduced Serum medium (Invitrogen), without serum and antibiotics, 
to attain the optimal final concentration. After gentle mixing, the optimised volume of PLUS 
Reagent was added to the diluted DNA and then incubated at room temperature for 5 min. 
Subsequently Lipofectamine LTX was added to the mix. Following 30 minutes of incubation at 
room temperature, the DNA-Lipid complexes were added dropwise to the plate containing cells. 
Fibroblasts were incubated at 37°C, 5% CO2 until ready to testing for transgene expression. 
Transfection conditions, including cell number, plasmid and Lipofectamine concentration, used for 
these experiments are reported in Table 4. 
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Culture 
Vessel 
Cell 
Number 
Volume 
plating 
medium 
Volume 
dilution 
medium 
DNA  
Plus 
Reagent  
Lipofectamine 
LTX  
35 mm 80,000 2 ml 500 µl 3 µg 3 µl 7.0 µl 
100 mm 600,000 10 ml 1000 µl 22 µg 22 µl 52.9 µg 
 
Table 4. Fibroblasts transfection conditions. 
 
4.5 Transfection of G157 and HEK293T cells 
G157 and HEK293T cells were transfected by lipid-mediated transfection with X-treameGENE HP 
DNA Transfection Reagent (Roche, Roche Diagnostic, Manheim, Germany), according to 
manufacturer’s instructions. Briefly, one day before transfection, cell were plated at the 
appropriated concentration in culture medium with FBS and without antibiotics. The day of 
transfection we prepared plasmid-lipid complex as follows: plasmid DNA was diluted into serum-
free medium, to reach the optimal final concentration. After mixing, the optimised volume of X-
treameGENE HP DNA Transfection Reagent was added to the diluted DNA, mixed and then 
incubated at room temperature for 20 min. Subsequently the transfection complexes were added 
dropwise to the plate containing cells, and then incubated at 37°C, 5% CO2 until ready to testing for 
transgene expression. Transfection conditions, including cell number, plasmid and Lipofectamine 
concentration, used for these experiments are reported in Table 5. 
 
Cells Medium 
Culture 
Vessel 
Cell 
Number 
Volume 
plating 
medium 
Volume 
dilution 
medium 
DNA 
X-treameGENE 
HP DNA  
G157 
RPMI 5% 
FBS 
35 mm 200,000 2 ml 400 µl 3 µg 9 µl 
100 mm 1,500,000 10 ml 1000 µl 22 µg 66 µl 
HEK 
DMEM 
10% FBS 
60 mm 1,000,000 5 ml 500 µl 6 µg  18 µl  
100 mm 2,000,000 10 ml 1000 µl  22 µg 66 µl 
 
Table 5. G157 and HEK cell lines transfection conditions 
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5. Immunofluorescence 
Immunofluorescence permits the visualisation of the subcellular localisation of a specific protein in 
cultured cells. 
For immunofluorescence experiments cells were seeded onto glass chamber slides and processed at 
around 70% confluence or at the end of transfection period (24 h). 
For better visualisation of centrosomes and microtubules, cells were washed in microtubule-
stabilising buffer for 4 min, fixed with methanol at -20°C for 12 min, and then permeabilized in 
PBS 0.1% Triton X-100 for 4 min. 
  
Microtubule-
stabilising 
buffer 
80 mM PIPES pH 6,9, 1 mM MgCl2, 1 mM EGTA, 
4% (w/v) polyethylene glycol 6,000 
 
Non-specific binding was blocked by incubating the fixed cells with 5% bovine serum albumin 
(BSA) in PBS for 20 min in a humidified chamber, before the incubation with primary antibodies. 
 
Primary antibodies and dilutions  
 Rabbit anti-MARK4 1+2+3+4 (phospho Thr 215) (ab111437, Abcam); 1:50 
 Mouse anti-γ-tubulin (clone GTU-88; Sigma); 1:200 
 Mouse anti-β-tubulin (clone TUB 2.1, Sigma);  1:100 
 Mouse anti-vimentin (sc-6260, Santa Cruz Biotechnology, Santa Cruz, CA, USA); 1:100 
 Mouse anti-Xpress (Invitrogen). 1:100 
 
Antibodies were diluted in PBS 0.1% Tween 20, 5% goat serum (the serum of the animal where the 
secondary antibodies are raised, goat, was used to reduce non-specific binding), and incubated 
overnight at 4°C. 
After three washes in PBS (10 min), the secondary antibodies, diluted in PBS 0.1% Tween 20 - 5% 
goat serum, were incubated for 1 hour at room temperature in dark humidified chamber. 
 
Primary antibodies and dilutions  
 Goat anti-rabbit IgG-FITC (Sigma); 1:200 
 Goat anti-mouse IgG-TRITC (Sigma). 1:200 
 
Following three washes of 8 minutes in PBS, the slides were mounted with DAPI antifade (Vector 
Labs, Burlingame, CA, USA) and examined using an Olympus IX51 inverted fluorescence 
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microscope, equipped with an Olympus DP71 super high-resolution colour digital camera and U-
MNIBA2 excitation 460/490 (FITC), U-MWIG3 excitation 530/550 (TRITC) and U-MNU2 
(DAPI) filters. Images were acquired and processed using the F-View II-Bund-cell F software 
(Olympus, Tokyo, Japan). 
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6. Protein Analyses 
6.1 Protein extraction 
Harvested cells were washed with cold PBS, counted and resuspended in lysis buffer (100 µl / 
2,000,000 cells). 
 
Lysis 
Buffer 
150 mM NaCl, 50 mM Tris pH 7.5, 1% NP-40, 0.25% deoxycholic acid, protease 
inhibitor cocktail (Complete EDTA-free, Roche) and phosphatase inhibitor (Halt™ 
Phosphatase Inhibitor Cocktail, Thermo Scientific). 
 
The suspension was incubated on ice for 30 minutes with occasional inversion to obtain complete 
lysis. The lysate was centrifuged at 14,000 rpm for 25 minutes, at 4°C to prevent protein 
degradation. The supernatant (whole cell lysate) was stored at -20°C.  
Protein concentration was determined by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA), 
according to the manufacturer’s protocol, with the ND-1000 Spectrophotometer. 
 
6.2 Co-immunoprecipitation 
Anti-vimentin antibody (sc-6260, Santa Cruz Biotechnology) was incubated with PureProteome™ 
Protein G Magnetic Beads (Millipore) for 1 hour at room temperature with continuous mixing. 
After three washes of the immobilised antibody in PBS containing 0.1% Tween 20, 1 mg of lysate 
was added and incubated at 4°C for 2h with agitation. Beads were extensively washed with PBS 
containing 0.1% Tween 20 and the immunoprecipitated proteins were eluted in non-reducing SDS 
loading buffer (Blue loading buffer pack, Cell Signaling Technology Inc., Beverly, MA, USA) by 
denaturating at 90°C for 10 minutes and subjected to SDS-PAGE, together with the corresponding 
whole cell lysates. 
 
6.3 Immunoblotting 
The immunoblotting procedure allows to separate proteins, according exclusively to their molecular 
weight, and to identify using specific antibodies, the presence or absence of a specific protein, its 
size and its relative expression.  
For each sample equal amounts of the extracted proteins (20 µg) were supplemented with reducing 
SDS loading buffer (Blue loading buffer pack, Cell Signaling Technology) and denatured 3 minutes 
at 99°C.  
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Proteins were then separated by 4% stacking (100V) and 10% resolving (130V) SDS 
PolyAcrylamide Gel Electrophoresis (SDS-PAGE). The separated proteins were transferred by 
semi-dry electroblotting (10V, 30 minutes) to a PVDF membrane (Roche). The molecular weight 
standard used were Biotinylated protein ladder (Cell Signaling Technology) and ColorBurst 
electrophoresis marker (Sigma). 
After electroblotting membranes were washed twice (10 min each) in PBS-T (0.3% Tween, Sigma) 
and non-specific binding was blocked by incubating the membrane in 5% skimmed milk, PBS-T for 
1 hours at RT, in agitation. 
 
PBS 100mM NaCl, 80mM Na2HPO4, 20mM NaH2PO4. 
 
Membranes were then incubated with appropriate primary antibodies in PBS-T at 4°C overnight in 
agitation. For protein quantification, the membranes were cut horizontally immediately after the 
blocking step and incubated with the appropriate antibodies. 
 
Primary antibodies and dilutions  
 Rabbit anti-MARK4L (GenScript corporation); 1:5,000 
 Goat anti-MARK4S (ab5262; Abcam); 1:1,250 
 Rabbit anti-MARK4 1+2+3+4 (phospho Thr 215) (ab111437, Abcam); 1:1,000 
 Mouse anti-vimentin (sc-6260, Santa Cruz Biotecnology); 1:1,000 
 Mouse anti-GAPDH (ab8245; Abcam). 1:10,000 
 
Following four washes in PBS-T membrane were incubated with secondary antibodies (in PBS-T) 
for 1 hour at room temperature (RT). 
 
Secondary antibodies and dilutions  
 Goat anti-rabbit IgG-HRP (sc-2004; Santa Cruz Biotechnology); 1:10,000 
 Donkey anti-goat IgG-HRP (sc-2020, Santa Cruz Biotechonlogy) 1:25,000 
 Anti-biotin, HRP-linked antibody (Cell Signaling). 1: 2,500 
The secondary antibodies are conjugated to HRP (Horse Radish Peroxidase), the 
anti-biotin antibody allows detecting the biotinylated protein ladder. 
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After four washes in PBS-T and two in PBS, bounded antibodies were detected by covering the 
membranes with peroxidase/enhancer solution (Westar ηC Cyanagene Bologna, Italy) for 5 minutes 
and Blot images were acquired with Gbox Chemi XT4 system (Syngene, Cambridge, UK). Semi-
quantitative analysis of MARK4L and MARK4S protein levels was performed using the Gene 
Tools Gel Analysis software (Syngene). MARK4L and MARK4S protein levels were normalised 
against GAPDH protein levels. 
For immunoblot with the anti-MARK 1+2+3+4 antibody (phospho Thr215), both primary and 
secondary antibodies were diluted in TBS-T (50 mM Tris, 150 mM NaCl, 0.3% Tween 20), 
membranes were washed in TBS-T/TBS, and TBS-T containing 5% bovine serum albumin (BSA) 
was used to block non-specific binding. 
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1. MARK4L and MARK4S expression during cell cycle phases 
To elucidate the function of MARK4 during cell cycle we first determined the expression profile of 
MARK4L and MARK4S during each specific cell cycle phase. To this purpose we performed bi-
parametric flow cytometry experiments on the glioblastoma G32 cell line, using PI to stain DNA 
content and specific antibodies to detect MARK4L or MARK4S protein expression. As negative 
control we used cells stained only with FITC-conjugated secondary antibody. Results of this 
analysis showed that MARK4L is not expressed at (a) particular cell cycle phase(s), but is 
continuously expressed throughout the cell cycle (Figure 1a). 
Similar results were obtained for MARK4S, which appeared to be expressed across all the cell cycle 
phases too (Figure 1b). Analogous results were achieved in fibroblasts (data not shown), allowing to 
generalise the main result obtained on glioma cells to normal cells. 
 
 
Figure 1. Cytofluorimetric analysis of MARK4L and MARK4S expression throughout the cell cycle of G32 
glioblastoma cells. Both MARK4L (a) and MARK4S (b) are expressed in all cell cycle phases. Cells stained 
with only FITC-conjugated secondary antibody were used as negative control. 
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2. Activation status of MARK4 during cell cycle 
As described in the introduction section, MARK4 activation requires the phosphorylation of the 
conserved Thr214 located in the activation loop. To asses phosphorylated-active MARK4 in human 
fibroblasts and glioma cells (G157), we performed immunofluorescence experiments using an 
antibody against all phosphorylated MARK proteins. The antibody was produced against the 
synthetic phosphopentapeptide L-D-T
P
-F-C, derived from human MARK 1+2+3+4 centred around 
the phosphorylation site of the threonine in the T-loop. This sequence is identical in all MARK 
proteins so its choice does not allow to raise antibodies specific for a single MARK protein. To 
overcome the limit given by the recognition of all phospho-MARKs we focused our attention on 
MARK4 subcellular localisation sites, centrosomes and midbody (Magnani et al., 2009; Magnani et 
al., 2011), which are not shared by the other MARK proteins and hence kept into account only 
signals in the above mentioned positions.  
MARK4 appeared phosphorylated throughout the cell cycle, with prevalence of the activated form 
in mitosis. In interphase, only a fraction of fibroblasts (about 29%) (Figure 2a) and G157 cells 
(nearly 31%) (Figure 2b) exhibited fluorescence corresponding to phosphorylated MARK4 at single 
or duplicated centrosomes. 
 
 
 
Figure 2. Immunofluorescence analysis of active MARK4 using an anti-phosphorylated MARK antibody. 
Representative images of phosphorylated-MARK4 (green) and γ-tubulin (red) immunostaining in interphase 
fibroblasts (a) and G157 cells (b). Centrosomes are labeled with phosphorylated-MARK4 (yellow 
arrowheads) only in a few cells.  
 
By contrast, MARK4 is phosphorylated during all phases of mitosis and cytokinesis. Fluorescence 
corresponding to phosphorylated MARK4 was always detected at centrosome during all mitotic 
stages (Figure 3d-f) and interestingly, also in the pre-mitotic phase during centrosome separation e 
migration (Figure 3a-c). 
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Active MARK4 is present also in the midbody during cytokinesis, especially at the borders of the 
midbody at the lateral constriction zone (Figure 3g-h). 
 
 
 
Figure 3. Immunofluorescence experiments of active MARK4 using an anti-phosphorylated MARK 
antibody. Representative images of G157 cells showing co-localisation between phosphorylated-MARK4 
(green) and γ-tubulin (red) immunostaining at centrosomes during centrosome separation (a-c) and across all 
phases of the mitosis (d-f). Positive signals are also visible at the midbody during cytokinesis (g and h). 
 
To verify that the signals detected by the phospho-MARK antibody at the centrosome are due to 
MARK4, we performed immunofluorescence experiments on MARK4S depleted fibroblasts. 
Following treatment with MARK4S or non-specific siRNA for 72 h, we verified the depletion of 
endogenous MARK4S by Western blot (Figure 4a) and performed immunofluorescence with the 
phospho-MARK antibody. In MARK4S siRNA treated cells a significant reduction of positive 
phospho-MARK4 signals as compared to non-specific control, can be observed at the interphase 
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centrosomes (10% vs 30%) (Figures 4b and c). These data suggest that the centrosome signals 
observed with the anti-phospho-MARK antibody are imputable to MARK4. 
 
 
 
 
Figure 4. Analysis of phospho-MARK4 in fibroblasts after MARK4S siRNA treatment for 72. (a) Western 
blot analysis of MARK4S protein levels, in MARK4S siRNA-treated human fibroblasts compared to levels 
in non-specific siRNA-treated control cells, show a decrease of MARK4S protein. The protein levels of 
MARK4S were normalised against the protein level of the housekeeping gene GAPDH. Representative 
images of phosphorylated-MARK4 (green) and γ-tubulin (red) immunostaining in non-specific siRNA-
treated control (b) and MARK4S siRNA-treated (c) fibroblasts. In MARK4S depleted cells a significant 
reduction of positive phospho-MARK4 signals as compared to non-specific control, can be observed.  
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3.Overexpression experiments 
3.1 Evaluation of MARK4L and MARK4S expression 
Before investigating the effects of MARK4 overexpression we verified that the GFP- and Xpress-
MARK4L/MARK4S fusion proteins were correctly expressed. We transfected HEK293T cells with 
the MARK4L or MARK4S vectors (both GFP and Xpress) and then analysed the presence of the 
recombinant proteins by Western blot using specific MARK4 antibodies. As shown in Figure 5, 
MARK4L and MARK4S are well expressed and recognised by their specific antibodies. 
Endogenous MARK4L is also detected by the anti-MARK4L antibody (Figure 5), at difference of 
MARK4S which is only weakly expressed by HEK cells.  
 
 
 
Figure 5. Immunoblot experiments of HEK293T cells overexpressing MARK4L or MARK4S. Both GFP- 
and Xpress-tagged proteins are expressed and recognised by the anti-MARK4L or anti-MARK4S antibodies. 
Endogenous MARK4L is also detected by the MARK4L antibody. NT, non-transfected; GFP L, 
overexpressed GFP-MARK4L; Xpress L, overexpressed Xpress-MARK4L; GFP S, overexpressed GFP-
MARK4S; Xpress S, overexpressed Xpress-MARK4S. 
 
 
We observed that a high expression level of MARK4L or MARK4S is cytotoxic. Therefore, in 
order to plan the timing of overexpression experiments, we decided to analyse the expression levels 
of the recombinant proteins at different post transfection times (4, 8, 24 and 48 h) in HEK293T 
cells. 
As shown in Figure 6 at 4h post-transfection both exogenous MARK4 isoforms were not yet 
detected by Western blot, indicating that monitoring should be delayed. Both MARK4L and 
MARK4S begin to be detectable 8 h after transfection, and their levels increase as expected at 24h. 
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At 48h the levels appear not increased in comparison to those at 24h, probably due to the death of a 
fraction of overexpressing cells (Figure 6).  
 
 
 
Figure 6. Western blot analysis of cells overexpressing MARK4L or MARK4S at 4h, 8h, 24h and 48h post-
transfection. Immunoblot analysis of HEK293T cells with ant-MARK4L or anti-MARK4S antibody shows 
that both MARK4 isoforms begin to be detectable 8 h after transfection. The expression levels increase at 
24h whereas remain stable at 48h. GAPDH was used as control protein. The membrane was cut after the 
blocking step and incubated with the appropriate antibodies. The MARK4L antibody also detects the 
endogenous MARK4L protein. NT, non-transfected; L, overexpressed MARK4L; S, overexpressed 
MARK4S. 
 
 
We then verified that the catalytically inactive MARK4 mutant (Kinase Dead, KD), in which 
Thr214 and Ser218 are substituted by alanine were correctly expressed in both fibroblasts and the 
G157 cell line. At 24 h post transfection both wild type and mutant MARK4L and MARK4S are 
well detectable by Western blot with specific MARK4 antibodies (Figure 7a). In addition the 
activation status of both overexpressed MARK4L and MARK4S was controlled by Western blot 
with the anti-phosphorylated MARK antibody. As proof of evidence for the correct working of the 
system wild-type MARK4L and MARK4S were found phosphorylated and thus active, whereas KD 
MARK4L and MARK4S were not (Figure 7b). 
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Figure 7. Western blot analysis of cells overexpressing MARK4L or MARK4S. (a) Immunoblot analysis of 
fibroblasts and G157 cells confirming the overexpression of wild-type MARK4L or MARK4S, and their KD 
mutants. (b) The anti-phosphorylated MARK antibody recognises overexpressed wild-type MARK4L and 
MARK4S but does not detect KD MARK4L or MARK4S (mutagenized at Thr214). GFP, GFP alone; L, 
overexpressed MARK4L; LKD, overexpressed KD MARK4L; S, overexpressed MARK4S; SKD, 
overexpressed KD MARK4S. 
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3.2 Overexpression of MARK4L or MARK4S reduces the density of the 
microtubule network 
As underlined in the introduction the main biological function of MARK proteins is to 
phosphorylate MAPs, leading to the destabilisation of microtubules. To investigate the effects of 
MARK4L and MARK4S on the MT network, we performed immunofluorescence experiments on 
our system of fibroblasts and G157 glioma cells transiently transfected with GFP-tagged wild-type 
MARK4L/MARK4S or the respective KD mutants. 
At 48 h after transfection, most cells overexpressing MARK4L or MARK4S had detached from 
chamber slides and died, confirming the cytotoxicity observed at this time and thus precluding 
monitoring the effect of MARK4L/MARK4S overexpression. Therefore, we selected for the 
analysis the 24 h post-transfection time, when the cells were still viable and exogenous MARK4L 
and MARK4S could be detected by Western blot (Figure 7). 
Immunofluorescence staining with an anti-β-tubulin antibody revealed that the MT network was 
altered in a large number of cells overexpressing MARK4L (Figures 8 and 9). In particular, the 
density of the MT network was lower in MARK4L overexpressing cells than in non-transfected 
cells or GFP-transfected cells (Figures 8 and 9). 
The effect of MARK4S overexpression was similar, in both the cell systems. Most of the 
transfected cells showed, as observed for MARK4L, an MT array less dense as compared to non-
transfected or GFP-transfected cells (Figures 8 and 9).  
To verify whether these alteration of MTs were caused by the kinase activity of the two MARK4 
isoforms, or by non-specific effects of overexpression, we transfected cell with catalytically inactive 
MARK4L or MARK4S mutants, in which Thr214 and Ser218 were mutated to alanine. In this case 
the recipient cells had a normal aspect and did not show any alteration of the microtubule network 
(Figures 8 and 9), demonstrating that the effects on microtubules can be ascribed to the 
phosphorylation activity of MARK4. 
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Figure 8. Effect of MARK4 overexpression on the MT network in fibroblasts. Immunofluorescence labeling 
with an anti-β-tubulin antibody (red) shows a reduced density of the MT network in fibroblasts 
overexpressing wild-type MARK4L or MARK4S (green) in comparison to surrounding non-transfected or 
GFP-transfected cells. Overexpression of KD MARK4L or MARK4S does not disrupt or weaken the MT 
network. 
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Figure 9. Effect of MARK4 overexpression on the MT network in G157 cells. Immunofluorescence labeling 
with an anti-β-tubulin antibody (red) shows a reduced density of the MT network in G157 cells 
overexpressing wild-type MARK4L or MARK4S (green) in comparison to surrounding non-transfected or 
GFP-transfected cells. Overexpression of KD MARK4L or MARK4S does not disrupt or weaken the MT 
network. 
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3.3 MARK4L co-localises with the intermediate filament protein vimentin in 
fibroblasts 
Microscopic observations of fibroblasts overexpressing MARK4L showed that many cells (more 
than 50% of transfected cells) displayed GFP fluorescence in a filamentous pattern that resembled 
the intermediate filament network, suggesting that MARK4 might interact with other cytoskeletal 
structures in addition to microtubules. In order to explore this hypothesis, we first excluded by 
immunofluorescence experiments with an anti-β-tubulin antibody, that the observed bundles contain 
microtubules. As shown in Figure 10 the anti-β-tubulin antibody did not label the filamentous 
pattern of overexpressed MARK4L, indicating that tubulin was not present in these filaments. 
 
 
 
Figure 10. Overexpressed MARK4L shows a filamentous pattern in fibroblasts. Immunofluorescence 
staining with an anti-β-tubulin antibody (red) highlights that the bundles observed in fibroblasts 
overexpressing MARK4L do not contain microtubules.  
 
Next we performed immunofluorescence experiments using an antibody against vimentin, the main 
component of intermediate filaments in fibroblasts. Overexpressed MARK4L appeared to localise 
to bundle structures that were also labelled with the anti-vimentin antibody (Figure 11). In contrast 
overexpressed MARK4S localised to these bundle structures to a lesser extent and only co-localised 
with the anti-vimentin antibody labelling in a few cells (less than 5%) (Figure 11).  
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Figure 11. Co-localisation of overexpressed MARK4L with intermediate filaments in fibroblasts. 
Overexpressed MARK4L (green) exhibits a filamentous pattern that co-localises with anti-vimentin antibody 
labelling (red). Overexpressed MARK4S shows a less evident co-localisation with vimentin. 
 
The co-localisation between MARK4L and vimentin is particularly evident in the perinuclear zone 
and in addition, in some overexpressing cells, vimentin filaments appeared re-structured as 
compared to those in GFP-transfected cells, and showed the formation of bundling (Figure 12).  
 
 
 
Figure 12. Comparison of intermediate filaments in GFP or MARK4L overexpressing fibroblasts. 
Immunofluorescence staining with an anti-vimentin antibody (red) shows that the intermediate filaments in 
MARK4L overexpressing fibroblasts are reorganised, forming bundle structures. In contrast overexpression 
of GFP alone does not alter their structure. 
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We next asked whether MARK4L activity is involved in the co-localisation with vimentin and in 
the reorganisation of these cytoskeletal filaments. We thus performed immunofluorescence 
experiments on fibroblasts transfected with kinase dead MARK4L. As shown in Figure 13, 
MARK4L KD in contrast to the wild type, does not alter the structure of intermediate filaments and 
co-localised to these fibres to a lesser extent (Figure 13). 
 
 
 
Figure 13. Effect of MARK4L wild type or kinase dead on vimentin filaments in fibroblasts. Overexpressed 
MARK4L (green) co-localises and alters the vimentin cytoskeleton (red). In contrast the kinase dead mutant 
(green) co-localises only partially with anti-vimentin antibody (red) and does not form bundle structures.  
 
Finally we asked whether MARK4L present in these structures is active and could exert its kinase 
functions and if the tag protein could influence this localisation. We thus transfected fibroblasts 
with pcDNA4/HisMax, a vector in which MARK4L is fused with the N-terminal-Xpreess™ tag, 
and then performed double immunofluorescence experiments with the anti-phspho-MARK1+2+3+4 
and with anti-Xpress antibodies. The overexpressed MARK4L showed the same filamentous pattern 
observed after transfection of GFP-MARK4L (Figure 14), demonstrating that the co-localisation 
with vimentin is not influenced by the tag. In addition the phospho-MARK antibody, co-localised 
with the recombinant MARK4L indicating that the protein is active (Figure 14). 
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Figure 14. Co-localisation between anti-Xpress and anti-phospho-MARK antibody signals. Overexpressed 
MARK4L fused with Xpress-tag (red) shows a filamentous pattern similar to that observed for GFP-
MARK4L and co-localises with the anti-phosphoMARK antibody labelling (green), indicating the 
phosphorylation of the exogenous protein.  
 
In order to better interpret the results of MARK4L overexpression we carried on co-
immunoprecipitation experiments in non-transfected fibroblasts to verify whether the endogenous 
MARK4L interacts directly with vimentin. Preliminary results using the anti-vimentin antibody, 
showed that vimentin interacts with MARK4L, since a band corresponding to MARK4L is detected 
in the vimentin immunoprecipitate sample (Figure 15).  
 
 
 
Figure 15. Co-immunoprecipitation of MARK4L and vimentin in normal fibroblasts. Whole cell lysate 
(WCL) of normal fibroblasts and immunoprecipitations (IP) with anti-vimentin or control mouse IgG (IgG) 
antibodies were analysed by immunoblotting with the indicated antibodies. A band corresponding to 
MARK4L is clearly visible in the vimentin IP sample. M: standard molecular masses. 
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Substantial evidence has been acquired on the important roles played by MARK4, a member of the 
MARK family of AMPK-related kinases, in the establishment and maintenance of cell polarity, in 
cell cycle control and in intracellular signal transduction (Drewes et al., 1997; Ebneth et al., 1999; 
Marx et al., 2010; Li & Guan 2013). For many years MARK4 remained the less characterised 
member of the MARK family and the functions ascribed to it were based on its homology to the 
other MARK proteins. Only recently an increasing number of studies focused on MARK4 functions 
have been published, delineating this protein as an extremely versatile and multifaceted kinase.  
As the least phylogenetically conserved of the MARK proteins, MARK4 has several unique 
features: the expression in two different isoforms, MARK4L and MARK4S, and a distinctive 
localisation at the centrosome and at the midbody during cytokinesis (Trinczek et al., 2004; 
Magnani et al., 2009; Magnani et al., 2011). The localisations of MARK4 at structures that are 
fundamental to cell division highlight its link with microtubules dynamics in cycling cells. Recent 
studies also revealed that MARK4 is a crucial regulator of MT-based structures, such as primary 
cilium, whose assembly is initiated at G0/G1 phase (Khuns et al., 2013), and ectoplasmic 
specialisations of rat testis spermatids and Sertoli cells, which are dependent on the tubulin 
cytoskeleton (Tang et al., 2012). 
Despite the increasing attention in literature about MARK4 function, the dual nature, represented by 
its two MARK4L and MARK4S isoforms, was scarcely addressed. In particular among the recent 
published studies, only one has focused on the role played by a single isoform, namely MARK4L 
(Khuns et al. 2013); notwithstanding the possible involvement of the second one was not evaluated.  
As already mentioned, the two MARK4 isoforms differ in the C-terminal region, suggesting 
different functions that could be directly mediated by the protein structure or depend on the specific 
proteins interacting with their differential end domain. In addition, the involvement of MARK4L 
and MARK4S in distinct processes is proposed by their different expression profiling in the central 
nervous system in both physiologic conditions during normal terminal differentiation and 
gliomagenesis (Beghini et al., 2003; Moroni et al., 2006; Magnani et al., 2011). 
In both these contexts deepening the possible differences between the short and long isoform in 
processes like cell cycle and cytoskeleton regulation appears to be of particular interest. Continuing 
our previous studies on MARK4, we wanted to further elucidate the role played by MARK4 in the 
cell cycle progression and in the regulation of the cytoskeleton in both normal (fibroblasts) and 
transformed cells (primary glioma cell lines). In particular we planned to face the intriguing 
problem of MARK4 dual nature, in order to highlight possible isoform-specific functions. 
To achieve this aim we first investigated the expression and activation status of MARK4 throughout 
the cell cycle, since protein kinases involved in cell cycle control are thinly regulated in their spatio-
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temporal expression and their activity is often acquired by post-translational modifications and 
protein-protein interactions (Bayliss et al., 2012). Accordingly, cytofluorimetric analysis showed 
that both MARK4 isoforms are not expressed during a particular cell cycle phase(s) but are 
continuously expressed throughout the cell cycle in both G32 glioblastoma cells and fibroblasts.  
We next performed immunofluorescence experiments to assess the activation of MARK4 in 
fibroblasts and glioma cells during cell cycle and established that MARK4 in its functionally active 
form prevails during mitosis and cytokinesis. As the antibody marking phospho-MARK4 is directed 
against an epitope shared by all MARK proteins and MARK4 can thus be only recognized through 
its peculiar centrosome localisation, shared by both MARK4 isoforms, this approach could not 
discriminate between MARK4S and MARK4L isoforms. In particular we highlighted that phospho-
MARK4 is present in the centrosome at all the mitotic phases and in the midbody during 
cytokinesis. In addition active MARK4 was also detected in centrosomes during their separation 
and migration to the cell poles. Interestingly, we have previously demonstrated that MARK4S 
depletion alters centrosome cycle and in particular depleted cells showed duplicated centrosomes 
positioned apically to the nucleus, that are unable to migrate (Rovina et al., submitted). Taken 
together these data support the involvement of MARK4 in the regulation of centrosome separation 
and migration. It has been demonstrated that the separation and migration of centrosomes involve 
microtubules and motor proteins, including both kinesin and dynein (Tanenbaum & Medema 2012). 
Interestingly MARK proteins have been reported to be involved in the regulation of microtubules 
and MT-based transport (Drewes et al., 1997; Mandelkow et al., 2004). The overall observations let 
us to hypothesize that MARK4 might regulate centrosome separation and migration through its 
action on microtubules and MT-transport. 
Overall, expression and activation data suggest that MARK4 is required throughout the cell cycle 
and phosphorylation of MARK4, which is required for its activation, mainly occurs during the 
dynamic phases of cell cycle including centrosome migration, mitosis and cytokinesis. 
Consistent evidences on MARK4 involvement in the regulation of cytoskeleton and cytoskeleton-
driving processes came from our overexpression experiments in both fibroblasts and glioma cell 
line (G157). These experiments allowed us to discriminate the effects of each single MARK4 
isoform making feasible to highlight possible different functions between them. 
Overexpression of MARK4L or MARK4S led to a sharp decrease in microtubule density in both 
fibroblasts and G157 cells, as monitored by immunofluorescence. By contrast, overexpression of 
KD MARK4L or MARK4S, in which the Thr214 and Ser218 residues of the phosphate acceptor 
site were mutated, did not affect the microtubule network, indicating that these effects on 
microtubules are dependent on the kinase activity of MARK4. 
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Our experiments highlight that both MARK4 isoforms have similar effects on the microtubules 
array in both normal and glioma cells. This datum is novel in two ways. First the two isoforms have 
been assayed for the first time in parallel; second their effect is monitored both in normal and 
glioma cells, allowing to generalise this function to physiological and pathological conditions. 
Indeed the activity exerted by both MARK4 isoforms on microtubules can be considered the main 
biological function of MARKs, since is shared by all the members of the family and can involve 
these kinases in the regulation of many different processes. However the distinctive subcellular 
localisation of MARK4, in addition to its different activation during cell cycle suggests that the 
microtubule depolymerisation activity could be directed to more specific processes namely mitosis 
and cytokinesis as compared to the other MARK proteins. 
The regulation of microtubules dynamics during mitosis and cytokinesis is tightly controlled by 
several proteins that act for the proper progression of these processes. Many studies have 
demonstrated that overstabilisation but also a decrease in the stability of MTs during mitosis result 
in an increased tendency to monopolar spindle formation (Tanenbaum & Medema 2012). Since we 
have shown that MARK4 regulates microtubules and is always active during mitosis, we can 
hypothesize that MARK4 plays an important role in bipolar spindle assembling, by regulating MTs 
dynamics. In addition the localisation of active MARK4 in the midbody, especially at the borders of 
the midbody in the lateral constriction zone, also suggests that MARK4 isoforms might be involved 
in the regulation of microtubule disassembly that starts just in the lateral midbody zone during 
abscission (Steigemann & Gerlich 2009).  
Taken together, our data on phosphorylated-MARK4 and overexpression show that active MARK4 
plays a key role in dynamic assembly/disassembly of the MT network during cell cycle and in 
particular in the organisation of the mitotic spindle from prophase to anaphase and the midbody at 
cytokinesis.  
The roles of MARK4 likely extend to other fundamental cytoskeleton structures, such as 
intermediate filaments, similar to other centrosomal kinases. For example, Aurora B not only 
controls centrosome separation, spindle formation and mitotic progression, but also phosphorylates 
vimentin during cytokinesis and thereby controls the assembly of intermediate filaments (Li & Li 
2006).  
Interestingly, in fibroblasts overexpressed MARK4L co-localises with vimentin in filament 
structures. Furthermore, this co-localisation is particularly evident in the perinuclear zone, and in 
some overexpressing cells, vimentin filaments appear more unorganised as compared to those in 
GFP-transfected cells, and show the formation of bundling structures (Figure 11-12). These 
alterations are clearly imputable to the kinase activity of MARK4L since overexpression of kinase 
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dead mutant did not remodel the intermediate filaments. In agreement with this data the 
overexpressed MARK4L present in these structures is demonstrated to be phosphorylated and thus 
able to exert its kinase function.  
In contrast to MARK4L, overexpressed MARK4S co-localises with vimentin to a lesser extent and 
only in few cells (about 5% of overexpressing fibroblasts). Interestingly, despite the two isoforms 
are strictly intermingled, as inferred by their shared subcellular localisation and by the common 
activity on MTs, their different co-localisation with vimentin structures might support a different 
role for them in the regulation of other cytoskeletal structures. A similar behaviour has been 
observed for the two isoforms of Oxysterol-binding-protein (OSPB)-related protein 4 (ORP4). 
Indeed ORP4-S co-localises with vimentin altering the structure of intermediate filaments, whereas 
ORP4-L displays a diffuse staining pattern (Wang et al., 2002). The strikingly different behaviour 
of MARK4L and MARK4S as regards vimentin co-localisation deserves further biochemical 
studies to be confirmed and to be interpreted.  
The three major components of the cytoskeleton interact with each other and their connections are 
important for many different functions including cell polarisation and motility. In particular the 
interaction between intermediate filaments and microtubules has been the focus of many studies 
highlighting the relevance of MTs for the correct organisation of intermediate filaments (Liem 
2013). Several proteins have been implicated in the connection between intermediate filaments and 
microtubules, and among them the role played by APC (Adenomatous polyposis coli) has been 
recently disclosed (Sakamoto et al., 2013). In particular it has been demonstrated that APC is 
required for microtubule interaction with intermediate filaments and for microtubule-dependent 
rearrangements of intermediate filaments during migration processes (Sakamoto et al., 2013). Our 
data suggest that MARK4L might be considered another bridging protein between the microtubules 
and the intermediate filament networks. In particular the long isoform could regulate the re-
organisation of these cytoskeleton structures that occurs during mitosis and cytokinesis. 
Phosphorylation is the main mechanism that regulates intermediate filaments functions (Omary et 
al. 2006) and it has been demonstrated that during mitosis intermediate filaments are 
phosphorylated in a spatio-temporal manner by distinct protein kinases (Sihag et al., 2007). In 
particular it has been reported that vimentin is phosphorylated by Cdk1 from prometaphase to 
metaphase (Tsujimura et al., 1994) and by Aurora-B (Goto et al,. 2003) and Rho-kinase (Goto et 
al., 1998) from anaphase to the end of mitosis. These phosphorylations regulate the structure and 
the separation of the vimentin filaments.  
Based on our data we are incline to hypothesize that MARK4L may act at this level, by 
phosphorylating vimentin and thus re-modelling the filament structure. As currently we do not have 
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any direct evidence of MARK4L-dependent phosphorylation, we are keeping into account as 
alternative mechanism that the re-organisation of intermediate filaments may be effected, through 
the regulation of MT-dependent transport, being thus connected to MARK4L indirectly. 
Interestingly bundle-like structures have been observed following overexpression of MAPs, and 
they have been thought to result from the stabilisation of intermediate filaments and their 
accumulation at the perinuclear zone (Trinczek et al., 1999). MAP overexpression inhibits the 
binding of motor proteins to MTs and thus prevents MT-based motility of intermediate filaments 
(Trinczek et al., 1999). Joining this evidence to that herein acquired on MTs destabilization, likely 
through increased MAPs phosphorylation, in MARK4 overexpressing cells, a reshaping of 
intermediate filaments, as described by Trinczek, might be envisaged. In our system MARK4 
overexpression by disrupting the MT scaffold might inhibit the movement of intermediate filaments 
along MTs thereby affect the dynamics of intermediate filaments.  
In conclusion, overexpression experiments demonstrate the important role played by MARK4 
isoforms in the regulation of cytoskeleton structures. A prevalence of active MARK4 is required 
during the dynamic phases of cell division. Moreover, the finding that MARK4L co-localises with 
intermediate filaments highlights the role of this protein in connecting different types of 
cytoskeletal filaments, as it has been reported for other centrosomal serine-threonine kinases. The 
overall data merge in demonstrating the dynamic involvement of MARK4L and MARK4S in 
structures like centrosomes, midbody and cytoskeleton, that are crucial for mitosis and cytokinesis. 
The emerging multifaceted role of MARK4 kinase in cell cycle paves the way for future studies 
aimed at establishing its interactions with the multiple proteins residing at the different 
cytoskeleton, centrosome and centrosome-related structures and their dynamic change during the 
cell cycle. 
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Perspectives  
We plan to develop this project on the two points of MARK4 phosphorylation and its co-
localisation with vimentin which we consider the most novel results. 
 
As concerns MARK4 switch to the active form, further advances will be focused to the following 
aim: 
 deepen the phosphorylation of MARK4 during interphase by co-staining with other cell 
cycle markers (PCNA, CENP-F for example) to delineate when phospho signal is first 
detected. 
 
In regards to the relationship of MARK4 with vimentin, experiments are in progress to:  
 
 confirm the interaction between MARK4L and vimentin by co-immunoprecipitation and in 
vitro binding assays; 
 
 verify the possible phosphorylation of vimentin by MARK4L; 
 
 analyse the soluble/insoluble ratio of vimentin following overexpression of MARK4. 
  
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77 
 
Alessi D.R., Sakamoto K. & Bayascas J.R. 
LKB1-Dependent Signaling Pathways. 
Annu Rev Biochem (2006); 75:137-63. 
 
Al-Hakim A.K., Zagorska A., Chapman L., Deak M., Peggie M. & Alessi D.R. 
Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked 
polyubiquitin chains.  
Biochem J (2008); 411:249–260. 
 
Amos L.A. & Schlieper D. 
Microtubules and maps. 
Adv Protein Chem (2005);71:257-98. 
 
Baas A.F., Boudeau J., Sapkota G.P., Smit L., Medema R., Morrice N.A., Alessi D.R. & Clevers 
HC.  
Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. 
EMBO J (2003); 22:3062–3072. 
 
Baas A.F., Smit L. & Clevers H. 
LKB1 tumor suppressor protein: PARtaker in cell polarity.  
Trends Cell Biol. (2004); 14(6):312-319. 
 
Bachmann M., Hennemann H., Xing P.X., Hoffmann I. & Möröy T.  
The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of 
Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle 
checkpoint.  
J Biol Chem (2004); 279: 48319–48328 
 
Bayliss R., Fry A., Haq T. & Yeoh, S.  
On the molecular mechanisms of mitotic kinase activation.  
Open Biol (2012); 2: 120-136. 
 
Beghini A., Magnani I., Roversi G., Piepoli T., Di Terlizzi S., Moroni R.F., Pollo B., Fuhrman Conti 
A.M., Cowell J.K., Finocchiaro G. & Larizza L.  
The neural progenitor- restricted isoform of the MARK4 gene in 19q13.2 is upregulated in 
human gliomas and overexpressed in a subset of glioblastoma cell lines.  
Oncogene (2003); 22:2581–2591. 
 
Benton R. & St Johnston D.  
Drosophila PAR-1 and 14-3-3 inhibit Bazooka/PAR-3 to establish complementary cortical 
domains in polarized cells.  
Cell (2003); 115:691-704. 
 
 
78 
 
Bessone S., Vidal F., Le Bouc Y., Epelbaum J., Bluet-Pajot M.T. & Darmon M. 
EMK protein kinase-null mice: dwarfism and hypofertility associated with alterations in the 
somatotrope and prolactin pathways.  
Dev Biol (1999); 214: 87–101. 
 
Bettencourt-Dias M. & Glover D.M.  
Centrosome biogenesis and function: centrosomics brings new understanding.  
Molecular Cell Biology (2007); 8:451-463 
 
Bohm H., Brinkmann V., Drab M., Henske A. & Kurzchalia T.V..  
Mammalian homologues of C. Elegans PAR-1 are asymmetrically localized in epithelial cells 
and may influence their polarity.  
Curr biol (1997); 7: R603-R606. 
 
Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutkowski M., Prescott A.R., Clevers 
H.C. & Alessi D.R.  
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and 
localize LKB1 in the cytoplasm. 
EMBO J (2003); 22:5102–5114. 
 
Brajenovic M., Joberty G., Kuster B., Bouwmeester T. & Drewes G.  
Comprehensive proteomic analysis of human Par protein complexes reveals an 
interconnected protein network.  
J Biol Chem (2004); 279:12804–12811. 
 
Bright N.J., Carling D. & Thornton C.  
Investigating the regulation of brain-specific kinases 1 and 2 by phosphorylation.  
J Biol Chem (2008); 283: 14946–14954. 
 
Chatterjee S., Sang T.K., Lawless G.M. & Jackson G.R. 
Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a 
Drosophila model. 
Hum Mol Genet (2009);18(1):164-177. 
 
Chen Y.M., Wang Q.J., Hu H.S., Yu P.C., Zhu J., Drewes G., Piwnica-Worms H. & Luo Z.G.. 
Microtubule affinity-regulating kinase 2 functions downstream of the PAR-3/PAR-6/atypical 
PKC complex in regulating hippocampal neuronal polarity.  
Proc Natl Acad Sci USA (2006); 103: 8534–8539. 
 
Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M. & Hyman B.T. 
Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary 
tangles in Alzheimer brain: a fluorescence resonance energy transfer study. 
J Neuropathol Exp Neurol (2000); 59(11):966-971. 
 
79 
 
Dequiedt F., Martin M., Von Blume J., Vertommen D., Lecomte E., Mari N., Heinen M.F., 
Bachmann M., Twizere J.C., Huang M.C., Rider M.H., Piwnica-Worms H., Seufferlein T. & 
Kettmann R. 
New role for hPar-1 kinases EMK and CTAK1 in regulating localization and activity of class 
IIa histone deacetylases.  
Mol Cell Biol (2006); 26: 7086–7102. 
 
Doxsey S., McCollum D. & Theurkauf W.  
Centrosomes in cellular regulation.  
Annu Rev Cell Dev Biol (2005a); 21: 411-434. 
 
Doxsey S, Zimmerman W, Mikule K. 
Centrosome control of the cell cycle. 
Trends Cell Biol (2005b);15(6):303-11. 
 
Drechsel D.N. & Kirschner MW. 
The minimum GTP cap required to stabilize microtubules. 
Curr Biol (1994);4(12):1053-1061. 
 
Drewes G., Ebneth A., Preuss U., Mandelkow E.M. & Mandelkow E.  
MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins 
and trigger microtubule disruption.  
Cell (1997); 89:297–308. 
 
Drewes G., Ebneth A., Mandelkow E.M.  
MAPs, MARKs and microtubule dynamics.  
Trends Biochem Sci (1998); 23(8):307-11. 
 
Drewes G. & Nurse P.  
The protein kinase kin1, the fission yeast orthologue of mammalian MARK/PAR-1, localises 
to new cell ends after mitosis and is important for bipolar growth.  
FEBS letters (2003); 554:45-49. 
 
Ebneth A., Drewes G., Mandelkow E.M. & Mandelkow E.  
Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of 
microtubules in cells.  
Cell Motil Cytoskeleton (1999); 44: 209-224. 
 
Espinosa L. & Navarro E.  
Human serine/threonine protein kinase EMK1: genomic structure and cDNA cloning of 
isoforms produced by alternative splicing.  
Cytogenet Cell Genet (1998); 81(3-4):278-282. 
 
 
80 
 
de Forges H., Bouissou A. & Perez F. 
Interplay between microtubule dynamics and intracellular organization. 
Int J Biochem Cell Biol (2012); 44(2):266-274. 
 
Fukasawa K.  
Introduction.  
Oncogene (2002); 21: 6140-6145. 
 
Gamblin T.C., Chen F., Zambrano A., Abraha A., Lagalwar S., Guillozet A.L., Lu M., Fu Y., 
Garcia-Sierra F., LaPointe N., Miller R., Berry R.W., Binder L.I. & Cryns V.L. 
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. 
Proc Natl Acad Sci USA (2003);100(17):10032-10037.  
 
Ganem N.J., Godinho S.A., and Pellman D.  
A mechanism linking extra centrosomes to chromosomal instability.  
Nature(2009); Vol. 460 DOI: 10.1038/nature08136. 
 
Goldman R.D., Cleland M.M., Murthy S.N., Mahammad S. & Kuczmarski E.R. 
Inroads into the structure and function of intermediate filament networks. 
J Struct Biol (2012);177(1):14-23. 
 
Goto H., Kosako H., Tanabe K., Yanagida M., Sakusai M., Amano M., Kaibuchi K. & Inagaki M. 
Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is 
specifically phosphorylated during cytokinesis. 
J Biol Chem (1998); 273: 11728–11736. 
 
Goto H., Yasui Y., Kawajiri A., Nigg E.A., Terada Y., Tatsuka M., Nagata K. & Inagaki M. 
Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic 
process. 
 J Biol Chem (2003); 278: 8526–8530. 
 
Götz J., Chen F., van Dorpe J. & Nitsch R.M. 
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. 
Science (2001); 293(5534):1491-1495. 
 
Gromley A., Yeaman C., Rosa J., Redick S., Chen C.T., Mirabelle S., Guha M., Sillibourne J. & 
Doxsey S.J. 
Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for 
secretory-vesicle-mediated abscission. 
Cell (2005);123(1):75-87. 
 
Guo S. & Kemphues K.J. 
Molecular genetics of asymmetric cleavage in the early Caenorhabditis elegans embryo. 
Curr Opin Genet Dev (1996); 6(4):408-415. 
81 
 
Gu G.J., Lund H., Wu D., Blokzijl A., Classon C., von Euler G., Landegren U., Sunnemark D. & 
Kamali-Moghaddam M. 
Role of individual MARK isoforms in phosphorylation of tau at Ser²
6
² in Alzheimer's disease. 
Neuromolecular Med (2013);15(3):458-469. 
 
Hardie D.G.  
Minireview:the AMP-activated protein kinase cascade: the key sensor of energy status.  
Endocrinology (2003); 144:5179-5183. 
 
Hartmann C., Johnk L., Kitange G., Wu Y., Ashworth L.K., Jenkins R.B. & Louis D.N.  
Transcript map of the 3.7 Mb D19S112-D19S246 candidate tumor suppressor region on the 
long arm of chromosome 19. 
Cancer Res (2002); 62: 4100-4108. 
 
Hayles J. & Nurse P. 
A journey into space. 
Nat Rev Mol Cell Biol (2001); 2(9):647-656. 
 
Hurov J.B., Stappenbeck T.S., Zmasek C.M., White L.S., Ranganath S.H., Russell J.H., Chan A.C., 
Murphy K.M. & Piwnica-Worms H.  
Immune system dysfunction and autoimmune disease in mice lacking Emk (Par-1) protein 
kinase.  
Mol Cell Biol (2001); 21: 3206–3219. 
 
Hurov J.B., Watkins J.L. & Piwnica-Worms H.  
Atypical PKC phosphorylates PAR-1 kinases to regulate localization and activity.  
Curr Biol (2004); 14: 736–741. 
 
Hurov J. & Piwnica-Worms H.  
The Par-1/MARK family of protein kinases: from polarity to metabolism.  
Cell Cycle (2007); 6:1966–1969. 
 
Inglis J.D., Lee M. & Hill R.E.  
EMK, a protein kinase with homologs in yeast maps to mouse chromosome 19.  
Mammal genome (1993); 4: 401-403. 
 
Jaleel M., Villa F., Deak M., Toth R., Prescott A.R., Van Aalten D.M. & Alessi D.R.  
The ubiquitin-associated domain of AMPK-related kinases regulates conformation and 
LKB1-mediated phosphorylation and activation.  
Biochem J (2006); 394: 545–555. 
 
 
 
 
82 
 
Janke C. & Kneussel M. 
Tubulin post-translational modifications: encoding functions on the neuronal microtubule 
cytoskeleton. 
Trends Neurosci (2010);33(8):362-372. 
 
Kato T., Satoh S., Okabe H., Kitahara O., Ono K., Kihara C., Tanaka T., Tsunoda T., Yamaoka Y., 
Nakamura Y. & Furukawa Y.  
Isolation of a novel human gene, MARKL1, homologous to MARK3 and its involvement in 
hepatocellular carcinogenesis. 
Neoplasia (2001); 3(1): 4-9. 
 
Katsetos C.D., Reddy G., Dráberová E., Smejkalová B., Del Valle L., Ashraf Q., Tadevosyan A., 
Yelin K., Maraziotis T., Mishra O.P., Mörk S., Legido A., Nissanov J., Baas P.W., de Chadarévian 
J.P. & Dráber P. 
Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic 
gliomas and human glioblastoma cell lines. 
J Neuropathol Exp Neurol (2006);65(5):465-477. 
 
Kuhns S., Schmidt K.N., Reymann J., Gilbert D.F., Neuner A., Hub B., Carvalho R., Wiedemann P., 
Zentgraf H., Erfle H., Klingmüller U., Boutros M. & Pereira G. 
The microtubule affinity regulating kinase MARK4 promotes axoneme extension during early 
ciliogenesis. 
J Cell Biol (2013); 200(4):505-22. 
 
Lawson J.L & Carazo Salas 
Microtubules: greater than the sum of the parts. 
Biochem Soc Trans (2013); 41(6):1736-1744. 
  
Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper 
L., Yager D., Eckman C., Hardy J., Hutton M. & McGowan E. 
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. 
Science (2001); 293(5534):1487-1491. 
 
Li J.J., & Li S.A. 
Mitotic kinase: the key to duplication, segregation, and cytokinesis errors, chromosomal 
instability, and oncogenesis.  
Pharmacol Ther (2006); 111; 974-984 
 
Li L.& Guan K.L. 
Microtubule-associated protein/microtubule affinity-regulating kinase 4 (MARK4) is a 
negative regulator of the mammalian target of rapamycin complex 1 (mTORC1). 
J Biol Chem (2013);288(1):703-708. 
 
 
83 
 
Liem R.K.H 
Intermediate filaments: not just for structure anymore. 
Curr Biol (2013); 23(8): R322-R324. 
 
Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boundeau J., Hawley S.A., Udd L., 
Mäkelä T.P., Grahame Hardie D., Alessi D.R.  
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including 
MARK/PAR-1.  
The EMBO Journal (2004); 23: 833–843. 
 
Magnani I., Guerneri S., Pollo B., Cirenei N., Colombo B.M., Broggi G., Galli C., Bugiani O., 
DiDonato S., Finocchiaro G. & Fuhrman-Conti A.M.  
Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de 
novo occurrence of cytogenetic alterations,  
Cancer Genetics and Cytogenetics (1994); 75: 77–89. 
 
Magnani I., Novielli C., Bellini M., Roversi G., Bello L. & Larizza L.  
Multiple localization of endogenous MARK4L protein in human glioma.  
Cell Oncol (2009); 31(5):357-370. 
 
Magnani I., Novielli C., Fontana L., Tabano S., Rovina D., Moroni R.F., Bauer D., Mazzoleni S., 
Colombo E.A., Tedeschi G., Monti L., Porta G., Bosari S., Frassoni C., Galli R., Bello L. & Larizza 
L. 
Differential signature of the centrosomal MARK4 isoforms in glioma. 
Anal Cell Pathol (Amst) (2011); 34(6):319-338. 
 
Mandelkow E.M. Thies E., Trinczek B., Biernat J.& Mandelkow E.  
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons.  
J Cell Biol (2004); 167(1): 99-110. 
 
Marx A., Nugoor C., Panneerselvam S. & Mandelkow E.  
Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of 
AMPK/Snf1-related kinases.  
FASEB J (2010); 24:1637-1648. 
 
Matenia D., Griesshaber B., Li X.Y., Thiessen A., Johne C., Jiao J., Mandelkow E. & Mandelkow 
E.M. 
PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic 
actin.  
Mol. Biol. Cell (2005); 16: 4410–4422 
 
Matenia D. & Mandelkow E.M. 
The tau of MARK: a polarized view of the cytoskeleton. 
Trends Biochem Sci (2009); 34(7):332-342. 
84 
 
 
Michelot A. & Drubin D.G. 
Building distinct actin filament networks in a common cytoplasm. 
Curr Biol (2011); 21(14):R560-9.  
 
Mitchison T & Kirschner M. 
Dynamic instability of microtubule growth. 
Nature (1984); 312(5991):237-242. 
 
Mollinari C., Lange B. & González C. 
Miranda, a protein involved in neuroblast asymmetric division, is associated with embryonic 
centrosomes of Drosophila melanogaster. 
Biol Cell (2002); 94(1):1-13. 
 
Moroni R.F., De Biasi S., Colapietro P., Larizza L. & Beghini A. 
Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating 
kinase 4 in differentiated neurons. 
Neuroscience. (2006); 143(1):83-94. 
 
Müller J. Ory S., Copeland T., Piwnica-Worms H. & Morrison D.K.  
C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffolds, KSR1.  
Molecular cell (2001); 8: 983-993. 
 
Müller J. Ritt D.A.,, Copeland T.D. & Morrison D.K.  
Functional analysis of C-TAK1 substrate binding and identification of PKP2 as a new C-
TAK1 substrate. 
EMBO J (2003); 22: 4431–4442. 
 
Mullins J.M. & Biesele J.J.  
Terminal phase of cytokinesis in D-98S cells.  
The journal of cell biology (1977); 73: 672-684. 
 
Mullins J.M. & McIntosh J.R. 
Isolation and initial characterization of the mammalian midbody. 
J Cell Biol (1982); 94(3):654-661. 
 
Murphy J.M., Korzhnev D.M., Ceccarelli D.F., Briant D.J., Zarrine-Afsar A., Sicheri F., Kay L.E. 
& Pawson T. 
Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition 
and promotes interaction with the adjacent kinase domain. 
Proc Natl Acad Sci USA (2007); 104(36):14336-14341. 
 
 
 
85 
 
Nesić D., Miller M.C., Quinkert Z.T., Stein M., Chait B.T. & Stebbins C.E. 
Helicobacter pylori CagA inhibits PAR1-MARK family kinases by mimicking host substrates. 
Nat Struct Mol Biol (2010);17(1):130-2. 
 
Nieminen M., Henttinen T., Merinen M., Ichihara F., Eriksson J.E. & Jalkanen S. 
Vimentin function in lymphocyte adhesion and transcellular migration. 
Nat Cell Biol (2006); 8(2):156-62.  
 
Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson 
M.P., Akbari Y. & LaFerla F.M. 
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta 
and synaptic dysfunction. 
Neuron (2003);39(3):409-421. 
 
Omary M.B., Ku N.O., Tao G.Z., Toivola D.M. & Liao J. 
"Heads and tails" of intermediate filament phosphorylation: multiple sites and functional 
insights. 
Trends Biochem Sci (2006);31(7):383-394. 
 
Pallari H.M. & Eriksson J.E. 
Intermediate filaments as signaling platforms. 
Sci STKE (2006); 2006(366):pe53. 
 
Panneerselvam S., Marx A., Mandelkow E.M. & Mandelkow E.  
Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-
1.  
Structure (2006); 14:173-183. 
 
Peng C.Y., Graves P.R., Ogg S., Thoma R.S., Byrnes M.J., 3rd, Wu Z., Stephenson M.T. & Piwnica-
Worms H.  
C-TAK1 protein kinase phosphorilates human Cdc25C on serine 216 and promotes 14-3-3 
protein binding.  
Cell Growth Differ (1998); 9:197-208. 
 
Perego P., Boiardi A., Carenini N., De Cesare M., Dolfini E., Giardini R., Magnani I., Martignone 
S., Silvani A., Soranzo C. & Zunino, F. 
Characterization of an established human, malignant, glioblastoma cell line (GBM) and its 
response to conventional drugs. 
 J Cancer Res Clin Oncol (1994); 120:585-592. 
 
Pohl C. & Jentsch S. 
Midbody ring disposal by autophagy is a post-abscission event of cytokinesis. 
Nat Cell Biol (2009);11(1):65-70. 
 
 
86 
 
Rapoport M., Dawson H.N., Binder L.I., Vitek M.P. & Ferreira A. 
Tau is essential to beta -amyloid-induced neurotoxicity. 
Proc Natl Acad Sci USA (2002);99(9):6364-6369. 
 
dos Remedios C.G., Chhabra D., Kekic M., Dedova I.V., Tsubakihara M., Berry D.A. & Nosworthy 
N.J. 
Actin binding proteins: regulation of cytoskeletal microfilaments. 
Physiol Rev (2003); 83(2):433-473. 
 
Riechmann V. & Ephrussi A.  
Axis formation during Drosophila oogenesis.  
Curr Opin Genet Dev (2001); 11(4):374-383. 
 
Roversi G., Pfundt R., Moroni R.F., Magnani I., van Reijmersdal, Pollo B., Straatman H., Larizza 
L. & Schoenmarkers E.F.P.M.  
Identification of novel genomic markers related to progression to glioblastoma through 
genomic profiling of 25 primary glioma cell lines.  
Oncogene (2006); 25: 1571-1583. 
 
Rovina D., Fontana L., Monti L., Novielli C., Panin N., Sirchia S.M., Erba E., Magnani I. & Larizza 
L. 
Microtubule-associated protein/microtubule affinity regulating kinase 4 plays a role in cell 
cycle progression and cytoskeletal dynamics. 
Submitted. 
 
Sakamoto Y., Boëda B.,& Etienne-Manneville S. 
APC binds intermediate filaments and is required for their reorganization during cell 
migration. 
J Cell Biol (0213); 200(3): 249-258. 
 
Sapir T., Sapoznik S., Levy T., Finkelshtein D., Shmueli A., Timm T., Mandelkow E.M. & Reiner O. 
Accurate balance of the polarity kinase MARK2/Par-1 is required for proper cortical 
neuronal migration. 
J Neurosci (2008); 28(22):5710-5720. 
 
Schaar B.T., Kinoshita K. & McConnell S.K..  
Doublecortin microtubule affinity is regulated by a balance of kinase and phosphatase activity 
at the leading edge of migrating neurons.  
Neuron (2004); 41: 203–213. 
 
Schmitt-Ulms G., Matenia D., Drewes G. & Mandelkow EM. 
Interactions of MAP/microtubule affinity regulating kinases with the adaptor complex AP-2 
of clathrin-coated vesicles. 
Cell Motil Cytoskeleton (2009); 66(8):661-672 
87 
 
 
Schoenenberger C.A., Mannherz H.G. & Jockusch B.M. 
Actin: from structural plasticity to functional diversity. 
Eur J Cell Biol (2011);90(10):797-804 
 
Segu, L., Pascaud, A., Costet, P., Darmon, M. & Buhot, M.C.  
Impairment of spatial learning and memory in ELKL Motif Kinase1 (EMK1/MARK2) 
knockout mice.  
Neurobiol Aging (2008) 29, 231–240. 
 
Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith 
A.V., Carassquillo M.M., Lambert J.C., Harold D. et al. 
Genome-wide analysis of genetic loci associated with Alzheimer disease. 
JAMA (2010); 303(18):1832-1840.  
 
Sihag R.K., Inagaki M., Yamaguchi T., Shea T.B. & Pant H.C. 
Role of phosphorylation on the structural dynamics and function of types III and IV 
intermediate filaments. 
Experimental Cell Research (2007); 313: 2098-2109. 
 
Sontag E., Nunbhakdi-Craig V., Lee G., Brandt R., Kamibayashi C., Kuret J., White C.L. 3rd, 
Mumby M.C. & Bloom G.S. 
Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications 
for the regulation of tau phosphorylation and the development of tauopathies. 
J Biol Chem (1999);274(36):25490-25498. 
 
Steigemann P. & Gerlich DW. 
Cytokinetic abscission: cellular dynamics at the midbody. 
Trends Cell Biol (2009);19(11):606-616. 
 
Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K., Kishikawa M., Hirose 
H., Amano Y., Izumi N., Miwa Y. & Ohno S.  
aPKC acts upstream of PAR-1b in both the establishment and maintenance of mammalian 
epithelial polarity.  
Curr Biol (2004); 14: 1425–1435. 
 
Tang E.I., Xiao X., Mruk D.D., Qian X.J., Mok K.W., Jenardhanan P., Lee W.M., Mathur P.P. & 
Cheng C.Y. 
Microtubule affinity-regulating kinase 4 (MARK4) is a component of the ectoplasmic 
specialization in the rat testis. 
Spermatogenesis (2012); 2(2):117-126. 
 
 
 
88 
 
 
Tanoue T. & Nishida E.  
Molecular recognitions in the MAP kinase cascades.  
Cell Signal (2003); 15:455–462. 
 
Tanenbaum M.E. & Medema R.H. 
Mechanisms of centrosome separation and bipolar spindle assembly. 
Dev Cell (2010);19(6):797-806 
 
Terabayashi T., Itoh T.J., Yamaguchi H., Yoshimura Y., Funato Y., Ohno S. & Miki H.  
Polarity-regulating kinase partitioning-defective 1/microtubule affinity-regulating kinase 2 
negatively regulates development of dendrites on hippocampal neurons.  
J Neurosci (2007); 27: 13098–13107. 
 
Timm T., Li X.Y., Biernat J., Jiao J., Mandelkow E., Vandekerckhove J. & Mandelkow, E.M. 
MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1.  
EMBO J (2003); 22:5090–5101. 
 
Timm T., Marx A., Panneerselvam S., Mandelkow E. & Mandelkow E.V.  
Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau 
protein.  
BMC Neuroscience 2008; 9 (Suppl2), S9. 
 
Tochio N., Koshiba S., Kobayashi N., Inoue M., Yabuki T., Aoki M., Seki E., Matsuda T., Tomo Y., 
Motoda Y., Kobayashi A., Tanaka A., Hayashizaki Y., Terada T., Shirouzu M., Kigawa T. & 
Yokoyama S. 
Solution structure of the kinase-associated domain 1 of mouse microtubule-associated 
protein/microtubule affinity-regulating kinase 3. 
Protein science 2006; 15: 2534-43. 
 
Toivola D.M., Tao G.Z., Habtezion A., Liao J. & Omary M.B. 
Cellular integrity plus: organelle-related and protein-targeting functions of intermediate 
filaments. 
Trends Cell Biol (2005);15(11):608-17. 
 
Trinczek B., Ebneth A., Mandelkow E.M. & Mandelkow E.  
Tau regulates the attachment/detachment but not the speed of motors in microtubule-
dependent transport of single vesicles and organelles.  
J Cell Sci (1999); 112: 2355-2367. 
 
Trinczek B., Brajenovic M., Ebneth A. & Drewes G.  
MARK4 is a novel Microtubule-associated Proteins/Microtubule affinity-regulating Kinase 
that binds to the cellular microtubule network and centrosomes.  
J Biol Chem (2004); 277: 5915-5923. 
89 
 
 
 
Tsujimura K., Ogawara M., Takeuchi Y., Imajoh-Ohmi S., Ha M.H. & Inagaki M. 
Visualization and function of vimentin phosphorylation by cdc2 kinase during mitosis.  
J Bio Chem (1994); 269:31097–31106. 
 
Uboha N.V., Flajolet M., Nairn A.C. & Picciotto M.R.  
A calcium- and calmodulin-dependent kinase I alpha/microtubule affinity regulating kinase 2 
signaling cascade mediates calcium-dependent neurite outgrowth.  
J Neurosci (2007); 27:4413–4423. 
 
Wang C., JeBailey L. & Ridgway N.D. 
Oxysterol-binding-protein (OSBP)-related protein 4 binds 25-hydroxycholesterol and 
interacts with vimentin intermediate filaments. 
Biochem J (2002);361(Pt 3):461-72. 
 
Wegner A. 
Head to tail polymerization of actin. 
J Mol Biol. 1976 Nov;108(1):139-50. 
 
Wullschleger S., Loewith R. & Hall M.N. 
TOR signaling in growth and metabolism. 
Cell (2006); 124(3):471-484. 
 
Yamamoto Y., Matsuyama H., Furuya T., Oga A., Yoshihiro S., Okuda M., Kawauchi S., Sasaki K. 
& Naito K. 
Centrosome hyperamplification predicts progression and tumor recurrence in bladder 
cancer. 
Clin Cancer Res (2004);10(19):6449-6455. 
 
Yu W., Polepalli J., Wagh D., Rajadas J., Malenka R. & Lu B. 
A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses 
and dendritic spines. 
Hum Mol Genet (2012); 21(6):1384-1390. 
 
Zempel H., Thies E., Mandelkow E. & Mandelkow E.M. 
αβ oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, 
Tau phosphorylation, and destruction of microtubules and spines. 
J Neurosci (2010);30(36):11938-11950. 
 
 
 
 
 
